# **RESEARCH ARTICLE**

Suprascapular nerve block is a clinically attractive alternative to interscalene nerve block during arthroscopic shoulder surgery: a meta-analysis of randomized controlled trials

Changjiao Sun<sup>1</sup>, Xiaolin Ji<sup>2</sup>, Xiaofei Zhang<sup>3</sup>, Qi Ma<sup>1</sup>, Peng Yu<sup>4</sup>, Xu Cai<sup>1\*†</sup> and Huadong Yang<sup>1\*†</sup>

# Abstract

Background: The interscalene brachial plexus block (ISB) is a commonly used nerve block technique for postoperative analgesia in patients undergoing shoulder arthroscopy surgery; however, it is associated with potentially serious complications. The use of suprascapular nerve block (SSNB) has been described as an alternative strategy with fewer reported side effects for shoulder arthroscopy. This review aimed to compare the impact of SSNB and ISB during shoulder arthroscopy surgery.

Methods: A meta-analysis was conducted to identify relevant randomized controlled trials involving SSNB and ISB during shoulder arthroscopy surgery. Web of Science, PubMed, Embase, Cochrane Controlled Trials Register, Cochrane Library, Highwire, CNKI, and Wanfang database were searched from 2010 through March 2021.

Results: We identified 1255 patients assessed in 17 randomized controlled trials. Compared with the ISB group, the SSNB group had higher VAS at rest in PACU (P = 0.003), 1 h after operation (P = 0.005), similar pain score 2 h (P = 0.39), 3-4 h (P = 0.32), 6-8 h after operation (P = 0.05), then lower VAS 12 h after operation (P = 0.00006), and again similar VAS 1 day (P = 0.62) and 2 days after operation (P = 0.70). As for the VAS with movement, the SSNB group had higher pain score in PACU (P = 0.03), similar VAS 4-6 h after operation (P = 0.25), then lower pain score 8-12 h after operation (P = 0.01) and again similar VAS 1 day after operation (P = 0.3) compared with the ISB group. No significant difference was found for oral morphine equivalents use at 24 h (P = 0.35), duration of PACU stay (P = 0.65), the rate of patient satisfaction (P = 0.14) as well as the rate of vomiting (P = 0.56), and local tenderness (P = 0.87). However, the SSNB group had lower rate of block-related complications such as Horner syndrome (P < 0.0001), numb (P = 0.002), dyspnea (P = 0.04), and hoarseness (P = 0.04).

\* Correspondence: sunchangjiao@163.com; yanghuadong2020@sina.com

<sup>†</sup>Xu Cai and Huadong Yang contributed equally to this work.

<sup>1</sup>Department of Orthopedic, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, No. 168 Litang Road, Dongxiaokou

RMC

# Town, Changping District, Beijing 102218, China

# Full list of author information is available at the end of the article



which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give

© The Author(s), 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License.





**Open Access** 

**Conclusion:** Our high-level evidence established SSNB as an effective and safe analgesic technique and a clinically attractive alternative to interscalene block with the SSNB'S advantage of similar pain control, morphine use, and less nerve block-related complications during arthroscopic shoulder surgery, especially for severe chronic obstructive pulmonary disease, obstructive sleep apnea, and morbid obesity. Given our meta-analysis's relevant possible biases, we required more adequately powered and better-designed RCT studies with long-term follow-up to reach a firmer conclusion.

Keywords: Nerve block, Regional, Suprascapular, Interscalene, Shoulder, Arthroscopy

# Background

Shoulder arthroscopic surgery can be associated with a 45% incidence of severe intraoperative and postoperative pain that can interfere with recovery and rehabilitation, which can be challenging to manage without large dose opioids. So, controlling postoperative pain while minimizing opioid administration is incredibly essential. Supplementing general anesthesia (GA) with a regional nerve block is recommended for reducing anesthesia's intra-operative requirements, improving the quality of

postoperative pain relief, easing postoperative rapid recovery [4, 5, 40].

Regional anesthetic techniques can control pain effectively, both at rest and on movement, allowing earlier mobilization without the adverse effects of opioids [36]. Among the various types of regional anesthetic techniques, the interscalene brachial plexus block (ISB) is a standard used nerve block technique for postoperative analgesia in patients undergoing shoulder surgery, as it has consistently been shown to significantly control



		מווס המוכוונס					
Study	Country	Sample sizes, n (SSNB/ISB)	Age, y, mean (SSNB/ISB)	% Female (SSNB/ISB)	BMI, kg/m <sup>2</sup> (SSNB/ISB)	Follow-up	Surgery
Abdallah 2020 [1]	Canada	67/69	46/40	NA	26.1/26.2	24 h	Shoulder arthroscopy
Auyong 2018 [3]	USA	60/61	55/54	33/40	28.9/27.8	24 h	Arthroscopic rotator cuff or Bankart repair
Cao 2019 [7]	China	25/25	57.72/56.8	40/60	24.69/24.38	48 h	Arthroscopic rotator cuff or Bankart repair
Desroches 2016 [11]	France	28/25	60.8/56.5	39/36	NA	7 d	Arthroscopic rotator cuff repair
lkemoto 2010 [20]	Brazil.	15/15	57/54	73.3/66.7	NA	48 h	Arthroscopic rotator cuff repair
Jiang 2017 [21]	China	24/23	56.4/55	62.5/65.2	23.2/22.9	24 h	Shoulder arthroscopy
Kumara 2016 [25]	India	30/30	NA	NA	NA	24 h	Shoulder arthroscopy
Li 2018 [28]	China	20/20	45.65/47.69	60/55	23.58/24	48 h	Shoulder arthroscopy
Lim 2020 [29]	Singapore	20/20	40.3/42.8	25/35	27/25.3	24 h	Shoulder arthroscopy
Liu 2020 [30]	China	54/53	NA	NA	NA	3 d	Shoulder arthroscopy
Mai 2019 [31]	China	60/60	56.7/56.6	63.3/65	323.2/23.4	12 h	Shoulder arthroscopy
Ovesen 2014 [34]	Denmark	23/22	48.95/48.70	70/50	NA	24 h	Arthroscopic subacromial decompression
Petroff 2020 [35]	Germany	24/24	50/52	42/50	25.8/26	24 h	Shoulder arthroscopy
Singelyn 2004 [40]	France	30/30	52/54	50/63	25.77/25.16	24 h	Arthroscopic acromioplasty
Wang 2019 [42]	China	20/21	48.7/50.86	55/52.4	23.47/22.83	24 h	Shoulder arthroscopy
Wiegel 2017 [43]	Germany	164/165	53/55	38		24 h	Shoulder arthroscopy
Yao 2019 [44]	China	48/47	53,6/54.1	37.5/40.4	24.4/24.8	24 h	Arthroscopic rotator cuff repair
Abbreviations: <i>SSNB</i> , suprascapu The detailed baseline characteri:	ular nerve block; <i>ISB</i> , ir stics information inclu	iterscalene block ding country, number of parti	cipants, age, gender, BMI, fo	llow-up time, and type	of surgery		

Table 1 Characteristics of included studies and patients

Sun et al. Journal of Orthopaedic Surgery and Research (2021) 16:376

# Table 2 Details of the nerve blocks and anesthesia used

Study	Localization method	Analgesia used in nerve block	Analgesia used in PACU	Analgesia used in ward
Abdallah 2020 [1]	Ultrasound guided	Local anesthetic solution in 5-ml aliquots	NRS > 4, IV fentanyl in 25- $\mu$ g increments every 5 min, as needed, up to a total of 100 $\mu$ g, followed by IV morphine in 5-mg incre- ments every 10 min up to a total of 20 mg or hydromorphone in 0.2-mg increments every 10 min up to a total of 3 mg.	Oral acetaminophen 300 mg plus codeine 30 mg combination tablets every 4 h, as needed, followed by oral oxycodone 5 to 10 mg every 4 h, as needed.
Auyong 2018 [3]	Ultrasound guided	15 mL of 0.5% ropivacaine	NRS pain score of 4-6, 25 mg of fentanyl IV; NRS score 7-10, 50 mg of fentanyl IV.	NRS score 4-6, 5 mg of oral oxycodone; NRS score 7-10, 10 mg of oral oxycodone.
Cao 2019 [7]	Arthroscopic guided (SNNB)/ Ultrasound guided (ISB)	20 mL of 0.2% ropivacaine	NA	100 mg of imrecoxib orally. If VAS > 3, 50 mg of flurbiprofen axetil IV; 6 h later, if VAS > 3, another 50 mg of flurbiprofen axetil IV; if VAS > 5, 50 mg of pethidine IM
Desroches 2016 [11]	Ultrasound guided	20 mL of 0.75% ropivacaine.	1 g of acetaminophen, 100 mg of ketoprofen, 100 mg of tramadol IV. If VAS > 3, 3 mg of morphine IV; 5 min later, if VAS > 3, another 3 mg of morphine IV	Acetaminophen (325 mg, 6 times a day), ketoprofen (100 mg, twice a day), pantoprazole(20 mg, once a day), tramadol (37.5 mg, 6 times a day). If still in pain, oral morphine sulfate (10 mg, 6 times a day).
lkemoto 2010 [20]	Anatomic landmarks guided	2 mg/kg of 0.5% ropivacaine	NA	NA
Jiang 2017 [21]	Ultrasound guided	20 mL of 0.375% ropivacaine+5mg of dexamethasone	If VAS > 4, 50 mg of pethidine IM	If VAS > 4, 50 mg of pethidine IM
Kumara 2016 [25]	Electrophysiology- guided	20 mL of 0.5% bupivacaine with 75 mg of clonidine	If VAS> 4, 75 mg of diclofenac IM	If VAS> 4, 75 mg of diclofenac IM
Li 2018 [28]	Ultrasound guided	20 mL of 0.375% ropivacaine	If VAS $>$ 4, tramadol IV	If VAS $>$ 4, tramadol IV
Lim 2020 [29]	Ultrasound guided	15 ml of 0.5% ropivacaine	Intravenous morphine (up to 0.2 mg/kg)	Regular oral paracetamol 1 g every 6 h and etoricoxib 120 mg once daily
<b>Liu 2020</b> [30]	Ultrasound guided	6 mL of 0.3% ropivacaine	NA	NA
Mai 2019 [31]	Ultrasound guided	20 mL of 0.375% ropivacaine+5 mg of dexamethasone	NA	NA
Ovesen 2014 [34]	Anatomic landmarks guided	20 mL of bupivacaine (SSNB)/ 30 mL of ropivacaine (ISB)	NA	1 g of paracetamol 4 times a day, 600 mg of ibuprofen 3 times a day. If VAS > 3, patients received 3-5 mg nicomorphine hydrochlor- ide IV followed by 5 mg ketobemidone.
Petroff 2020 [35]	Ultrasound guided	10 ml of 1% ropivacaine	NA	lbuprofen 600 mg up to four times or the synthetic opioid tilidine 100 mg up to twice in 24 h, as needed.
Singelyn 2004 [40]	Anatomic landmarks guided	10 mL of 0.25% bupivacaine (SSNB)/ 20 mL of 0.25% bupivacaine (ISB)	If VAS $>$ 3, 2 g of IV propacetamol, 30 min, if VAS $>$ 3 5 or 10 mg of subcutaneous morphine	If VAS $>$ 3, 2 g of IV propacetamol, 30 min, if VAS $>$ 3 5 or 10 mg of subcutaneous morphine
Wang 2019 [42]	Ultrasound guided	15 mL of 0.5% ropivacaine	If VAS $>$ 3, tramadol IV	If VAS $>$ 3, tramadol IV
Wiegel 2017 [43]	Ultrasound guided	10 mL of 1% ropivacaine/20 mL of 0.75% ropivacaine	If NRS > 3, 3 mg of IV piritramide	If NRS $>$ 3, 3 mg of IV piritramide
Yao 2019 [44]	Ultrasound guided	15 mL of 0.5% ropivacane (SSNB)/20 mL of 0.5% ropivacaine (ISB)	If VAS > 3, 100 mg of tramadol IV, 10 min, if VAS > 3, 3 mg of morphine IV.	300 mg of oral ibuprofen 3 times a day, if VAS > 3, 100 mg of Tramadol IV; 10 min, if VAS >3, 2 mg of hydromorphone hydrochloride IM

Abbreviations: SSNB, suprascapular nerve block; ISB, interscalene block; IV, intravenous; IM, intramuscular; NRS, numerical rating scale; VAS, visual analog scale; PACU, postanesthesia care unit; US, ultrasound

Details of the nerve blocks and anesthesia used including localization method, analgesia, used in nerve block, analgesia used in PACU and analgesia used in ward



**Fig. 2** Risk of bias summary for included studies. +, no bias; –, bias; ?, bias unknown. Fifteen studies adequately described the correct randomization. Sixteen studies demonstrated sufficient allocation concealment. Eight studies described the blinding of participants and personnel. All seventeen articles described the blinding of outcome assessment, retained complete outcome data, and avoided selective reporting. We rated as unclear risk of other bias because we cannot ignore other potential dangers of biases

postoperative pain, even in a small dose or single dose [2, 17, 18, 24, 26]. Moreover, ISB can be used to provide either surgical anesthesia or postoperative anesthesia. Many studies have demonstrated that ISB provides optimal analgesia in shoulder arthroscopic surgery in success rates of 87-100% [36]. Although it is useful for postoperative analgesia, ISB is challenging to perform, and it is associated with potentially serious complications such as diaphragmatic paresis from the phrenic nerve block, pneumothorax, brachial plexus injury, extended motor block inadvertent epidural anesthesia, and vertebral artery injection [15, 27]. Furthermore, there are relative contraindications in patients with severe chronic obstructive pulmonary disease because of phrenic nerve issues [15]. This clinical problem has recently received considerable attention, with several calls to seek alternatives to interscalene block in shoulder arthroscopy [9]. So, the need for a safer ISB alternative has prompted researchers to examine several options, including but not limited to the suprascapular block [14]. The suprascapular nerve block (SSNB) technique is a simple, easily reproducible technique that is thought to supply sensory fibers to approximately 70% of the shoulder joint and directly innervates the supraspinatus and infraspinatus muscles. The most common complication of SSNB is transient nerve palsy [6]. We found few studies comparing the efficacy of SSNB and ISB for arthroscopic shoulder surgery. Some have found ISB to be superior [23, 39], whereas others have shown that SSNB provides noninferior analgesia [11, 25]. Our meta-analysis was to compare the analgesic efficacy of SSNB with ISB after shoulder arthroscopy.

# Methods

The current meta-analysis was registered on PROSPERO (International prospective register of systematic reviews) and the registration number was CRD42020205426.This meta-analysis was performed using a predetermined protocol following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement to assess the results' quality to make sure our meta-analysis's results reliable and veritable.

# Search strategy

SSNB and ISB during shoulder arthroscopy surgery. Web of Science, PubMed, Embase, Cochrane Controlled Trials Register, Cochrane Library, Highwire, CNKI, and Wanfang database were searched from 2010 through March 2021. The keywords used were "nerve block," "regional," "suprascapular," "interscalene," "shoulder," "arthroscopic," randomized controlled trials" in conjunction with Boolean operators "AND" or "OR." We used Review Manager Software for MAC to perform the meta-analysis.

#### Inclusion criteria

Studies were eligible if (1) the intervention was patients undergoing shoulder arthroscopic surgery with SSNB; (2) the comparator was patients undergoing shoulder arthroscopic surgery with ISB; (3) the study design was a randomized controlled trial (RCTs); and (4) the studies were required to contain at least one clinical outcome data. The exclusion criteria were as follows: (1) observational studies; (2) non-RCTs; and (3) studies with insufficient clinical outcome data.

### Data extraction process

Two reviewers (C.J.S and Q.M.) used a standardized form to extract data. A third reviewer (H.D.Y.) was used to resolve disagreements in eligibility, data extraction, or quality assessment. Extracted data included the primary data based on the following: first author, year of publication, participants, age, gender, body mass index, followup time, type of surgery, localization method, analgesia used in nerve block, analgesia used in PACU, and analgesia used in the ward. The included studies evaluated pain score with similar scores like VAS or NRS which is a line with anchor statements on the left (no pain) and on the right (extreme pain). Therefore, we equate NRS with VAS in statistical analysis. Because there were different kinds of opioid drugs in different studies and some are intravenous opioid drugs, some are oral opioid drugs. To reduce heterogeneity, we have converted various opioids drugs into the same morphine (oral). Conversions of amounts of different opioids used were performed using a web-based opioid conversion calculator (https://globalrph.com/medcalcs/opioid-conversions-calcoriginal-single-agent/).

# Assessment of studies

The studies' methodological quality was assessed following the instructions in the Cochrane Handbook for Systematic Reviews of Interventions.

### Statistical analysis

RevMan software (version 5.3; The Cochrane Collaboration) was used for the analysis. We used a random-effects model for all analyses, as clinical heterogeneity was assumed to exist because of differences in standardization in anesthetic, nerve block techniques, diversity of shoulder surgeries performed, and the timing of assessment across studies. Data were summarized as the ratio of relative risk (rate of patient satisfaction, complications including the rate of subjective dyspnea, hoarseness, vomiting, local tenderness, Horner syndrome, and numb) or the difference between means (VAS at rest, VAS with movement, oral morphine equivalents use at 24 h and duration of PACU stay). Studies that did not report standard deviations (SDs) were calculated from p values, confidence intervals, or standard errors. The results were considered as a statistically significant difference when P values were less than 0.05.

# Results

The literature search identified 389 citations. Of these, 290 duplicates were removed. After reviewing the 99 remaining articles' titles and abstracts, we excluded 74 papers according to the inclusion and exclusion criteria; 25 full texts were retrieved. Because some articles did not compare the suprascapular nerve block with interscalene nerve block, five studies were excluded. Finally, we identified 1255 patients assessed in 17 randomized controlled trials [1, 3, 7, 11, 20, 21, 25, 28–31, 34, 35, 40, 42–44] (Fig. 1). Study baseline characteristics and



Study or Subgroup	Suprascap Mean	ular nerve block SD To	a Interscale Interscale	ne nerve l SD	olock Total	Weight	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% Cl
1.1.1 PACU Abdallah 2020 Auyong 2018 Desroches 2016 Ikemoto 2010 Jiang 2017 Kumara 2016 Liu 2020 Ovesen 2014 Singelyn 2004 Wang 2019 Wiegel 2017 Yao 2019 <b>Subtotal (95% CI)</b> Heterogeneity: Tau <sup>2</sup> = Test for overall effect	1.3 2 2.4 5.87 1.8 4.1 1.51 1.73 0.96 3.8 2.01 1.47 2.48 • 0.33; Chi <sup>2</sup> = 7 = 2.94 (P =	2.2 3 2.8 2 0.8 2.16 0.41 0.72 1.73 2 0.41 0.85 1 1.59 5 86.35, df = 12 +	67 0.6 63 2 28 0.8 15 6.27 24 1.7 30 2.03 20 1.52 54 1.76 23 0.09 30 0.8 20 1.52	2.2 2.9 2.3 2.2 0.8 2.53 0.68 0.43 1.6 0.77 0.91 1.42 2 = 86%	69 63 15 23 30 20 53 22 30 21 165 27 <b>563</b>	1.7% 1.3% 0.9% 0.8% 2.1% 1.1% 2.3% 2.4% 1.7% 2.4% 2.4% 2.4% 2.4% 2.1,7% 21.9%	$\begin{array}{c} 0.70 \left[-0.04, 1.44\right]\\ 0.00 \left[-1.03, 1.03\right]\\ 1.69 \left(0.23, 2.97\right]\\ -0.40 \left[-1.90, 1.10\right]\\ 0.10 \left[-0.35, 0.56\right]\\ 2.07 \left[0.88, 3.26\right]\\ -0.01 \left[-0.32, 0.30\right]\\ 0.03 \left[-0.30, 0.24\right]\\ 0.87 \left[0.14, 1.60\right]\\ 3.00 \left[2.08, 3.92\right]\\ 0.49 \left[0.11, 0.87\right]\\ 0.74 \left[0.04, 1.144\right]\\ 0.56 \left[0.19, 0.94\right]\\ \end{array}$	
1.1.2 1 h Auyong 2018 Kumara 2016 Yao 2019 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> Test for overall effect	2.6 3.27 2.55 = 0.15; Chi <sup>2</sup> = = Z = 2.81 (P	2.7 1.48 1.68 1 3.70, df = 2 (P =	$\begin{array}{cccc} 63 & 2.1 \\ 30 & 1.67 \\ 48 & 1.87 \\ 41 \\ = 0.16); I^2 = 469 \end{array}$	2.6 1.86 1.36	63 30 27 <b>120</b>	1.4% 1.5% 1.7% <b>4.6%</b>	0.50 [-0.43, 1.43] 1.60 [0.75, 2.45] 0.68 [-0.02, 1.38] <b>0.92 [0.28, 1.57]</b>	
1.1.3 2 h Cao 2019 Kumara 2016 Yao 2019 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overal effect	1 2.53 2.28 = 0.02; Chi <sup>2</sup> = = Z = 0.86 (P =	0.25 0.82 1.31 2.52, df = 2 (P = = 0.39)	$\begin{array}{cccc} 25 & 1 \\ 30 & 1.93 \\ 48 & 1.97 \\ 103 \\ = 0.28); \  ^2 = 219 \end{array}$	0.5 2.35 1.03	25 30 27 <b>82</b>	2.4% 1.4% 2.0% 5.8%	0.00 [-0.22, 0.22] 0.60 [-0.29, 1.49] 0.31 [-0.23, 0.85] <b>0.12 [-0.16, 0.40]</b>	
1.1.4 3-4h Cao 2019 Kumara 2016 Ovesen 2014 Singelyn 2004 Wiegel 2017 Yao 2019 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect	1 2.87 1.7 1.9 1.53 2.32 = 0.20; Chi <sup>2</sup> = : Z = 0.99 (P =	0.125 1.31 1.66 1.8 0.82 1 1.27 <b>3</b> 50.10, df = 5 (P = 0.32)	25 1 30 2.6 23 0.68 30 0.7 164 2.11 48 2.11 20 2 < 0.00001);   <sup>2</sup>	0.25 1.55 1.25 1.4 0.81 1.14 = 90%	25 30 22 30 165 27 <b>299</b>	2.5% 1.7% 1.5% 1.5% 2.4% 1.9% <b>11.6%</b>	0.00 [-0.11, 0.11] 0.27 [-0.46, 1.00] 1.02 [0.16, 1.88] 1.20 [0.38, 2.02] -0.58 [-0.76, -0.40] 0.21 [-0.35, 0.77] 0.21 [-0.21, 0.64]	
1.1.5 6-8h Abdallah 2020 Cao 2019 Desroches 2016 Ikemoto 2010 Jiang 2017 Kumara 2016 Li 2018 Liu 2020 Wang 2019 Yao 2019 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect	1.2 2.52 2.75 5.53 1.9 2.87 1.72 2.17 1.72 2.43 $e 0.09; Chi^2 = 1.94 (P = 1)$	1.6 1.48 2 3 0.9 1.31 0.67 0.85 0.67 1.35 <b>3</b> 18.29, df = 9 (P 0.05)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	1.6 2.6 2 2.5 1.2 1.55 0.83 0.78 0.83 1.29	69 25 25 23 30 20 53 21 27 <b>308</b>	2.0% 1.1% 1.2% 0.5% 1.9% 1.7% 2.1% 2.3% 2.1% 1.8% <b>16.7%</b>	$\begin{array}{c} -0.50 \left[ -1.04, 0.04 \right] \\ -1.28 \left[ -2.45, -0.11 \right] \\ 0.40 \left[ -0.68, 1.48 \right] \\ -0.14 \left[ -2.12, 1.84 \right] \\ 0.00 \left[ -0.61, 0.61 \right] \\ 0.27 \left[ -0.45, 1.00 \right] \\ -0.89 \left[ -1.36, -0.42 \right] \\ -0.17 \left[ -0.48, 0.14 \right] \\ -0.59 \left[ -0.56, -0.04 \right] \\ 0.21 \left[ -0.41, 0.83 \right] \\ -0.28 \left[ -0.56, 0.00 \right] \end{array}$	
1.1.6 12 h Abdallah 2020 Cao 2019 Jiang 2017 Li 2018 Liu 2020 Mai 2019 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect	3.4 3.32 2.3 2.13 2.45 2.3 2.13 2.13 2.45 2.3 2.13 2.13 2.13 2.13 2.13 2.13 2.13	3 1.55 1.3 0.91 1.01 0.7 0.91 2 21.74, df = 6 (P = 0.0006)	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	3 2.3 1.2 0.99 0.97 0.9 0.99 72%	69 25 23 20 53 60 21 <b>271</b>	1.3% 1.2% 1.7% 1.9% 2.2% 2.3% 1.9% <b>12.5%</b>	-0.30 [-1.31, 0.71] -1.36 [-2.45, -0.27] -0.30 [-1.01, 0.41] -0.60 [-1.19, -0.01] -1.42 [-1.80, -1.04] -0.40 [-0.69, -0.11] -0.66 [-1.18, -0.02] -0.71 [-1.12, -0.30]	
1.1.7 1 d Abdallah 2020 Auyong 2018 Cao 2019 Desroches 2016 Ikemoto 2010 Jiang 2017 Kumara 2016 Li 2018 Liu 2020 Ovesen 2014 Singelyn 2004 Wang 2019 Wiegel 2017 Yao 2019 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect	5.1 1.4 2.6 2.9 5.13 3.6 3.2 2.74 3.79 3.21 1.1 2.74 2.56 3.11 * 0.77; Chi <sup>2</sup> = Z = 0.49 (P *	2.5 1.7 1.35 2 4 1.2 0.99 0.82 1.28 2.5 1.3 0.82 1.23 1 1.7 6 118.02, df = 13 = 0.62)	67 4.5 60 1.8 25 3.56 28 2.9 15 3.8 24 3.2 30 1.6 20 3.46 54 6.04 23 3.09 30 1.6 20 2.46 164 2.59 48 3.23 508 8 (P < 0.00001);	$\begin{array}{c} 2.5\\ 2.1\\ 1.39\\ 2.1\\ 3\\ 1.3\\ 1.4\\ 0.67\\ 1.42\\ 2.49\\ 1.4\\ 0.67\\ 1.17\\ 1.86\\ l^2=89\% \end{array}$	69 61 25 25 15 30 20 53 20 20 21 165 27 <b>586</b>	1.5% 1.8% 1.2% 0.4% 1.7% 2.1% 2.0% 0.8% 2.1% 2.1% 2.4% 1.5% <b>22.6%</b>	0.60 [-0.24, 1.44] -0.40 [-1.08, 0.28] -0.96 [-1.72, -0.20] 0.00 [-1.11, 1.11] .133 [-1.20, 3.86] 0.40 [-0.32, 1.12] -0.72 [-1.18, -0.26] -2.25 [-2.76, -1.74] 0.12 [-1.34, 1.58] -0.50 [-1.18, 0.74] -0.38 [-0.18, 0.74] -0.12 [-0.98, 0.74] -0.12 [-0.98, 0.74] -0.12 [-0.98, 0.74] -0.13 [-0.64, 0.38]	
1.1.8 2 d Cao 2019 Ikemoto 2010 Li 2018 Subtotal (95% CI) Heterogenity: Tau <sup>2</sup> = Test for overall effect	2.28 3.53 3.27 = 0.07; Chi <sup>2</sup> = = Z = 0.38 (P =	0.94 1.25 0.98 2.68, df = 2 (P = = 0.70)	$\begin{array}{ccccccc} 25 & 2.92 \\ 15 & 3 \\ 20 & 3.27 \\ 60 \\ = 0.26); \ l^2 = 259 \end{array}$	1.96 2 1.32	25 15 20 <b>60</b>	1.5% 1.1% 1.7% <b>4.3%</b>	-0.64 [-1.49, 0.21] 0.53 [-0.66, 1.72] 0.00 [-0.72, 0.72] -0.12 [-0.71, 0.48]	
Total (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect Test for subgroup dif Fig. 4 (See legend on next	= 0.27; Chi <sup>2</sup> = : Z = 0.37 (P = ferences: Chi <sup>2</sup> page.)	24 379.51, df = 58 = 0.71) = 34.20, df = 7	19 3 (P < 0.00001); ' (P < 0.0001), I <sup>2</sup>	l <sup>2</sup> = 85% = 79.5%	2289	100.0%	0.03 [-0.13, 0.19] -	-4 -2 0 2 4 Suprascapular nerve block Interscalene nerve block

(See figure on previous page.)

```
Fig. 4 A forest plot diagram showing VAS at rest. The pooled results showed that SSNB group had higher VAS at rest in PACU (MD = 0.56, 95\% CI [0.19, 0.94], P = 0.003) and 1 h after operation (MD = 0.92, 95\% CI [0.28, 1.57], P = 0.005), however, lower VAS at 12 h after operation (MD = -0.71, 95\% CI [-1.12, -0.3], P = 0.0006). No significant difference was found for VAS at rest 2 h after operation (MD = 0.12, 95\% CI [-0.16, 0.4], P = 0.39), 3-4 h (MD = 0.21, 95\% CI [-0.21, 0.64], P = 0.32), 6-8 h (MD = -0.28, 95\% CI [-0.56, 0.00], P = 0.05), 1 day (MD = -0.13, 95\% CI [-0.64, 0.38], P = 0.62), and 2 days after operation (MD = -0.12, 95\% CI [-0.71, 0.48], P = 0.7)
```

general intervention information are summarized in Tables 1 and 2.

The risk of bias summary and bias graph for RCTs is shown in Figs. 2 and 3. Fifteen studies adequately described the correct randomization. Sixteen studies demonstrated sufficient allocation concealment. Eight studies described the blinding of participants and personnel. All seventeen articles described the blinding of outcome assessment, retained complete outcome data, and avoided selective reporting. We rated as unclear risk of other bias because we cannot ignore other potential dangers of biases. As a result, there is a low or moderate risk of bias in most of the articles reviewed.

#### Outcome

## VAS at rest

The pooled results showed that SSNB group had higher VAS at rest in PACU (MD = 0.56, 95% CI [0.19, 0.94], P = 0.003) and 1 h after operation (MD = 0.92, 95% CI [0.28, 1.57], P = 0.005), however, lower VAS at 12 h after operation (MD = -0.71, 95% CI [-1.12, -0.3], P = 0.0006). No significant difference was found for VAS at rest 2 h after operation (MD = 0.12, 95% CI [-0.16,0.4], P = 0.39), 3-4 h (MD = 0.21, 95% CI [-0.21, 0.64], P = 0.32), 6-8 h (MD = -0.28, 95% CI [-0.56, 0.00], P = 0.05), 1 day (MD = -0.13, 95% CI [-0.64, 0.38], P = 0.62), and 2 days after operation (MD = -0.12, 95% CI [-0.71, 0.48], P = 0.7) (Fig. 4).

# VAS with movement

The pooled results showed that SSNB group had higher VAS with movement in PACU (MD = 1.05, 95% CI [0.1, 2], P = 0.03), however, lower VAS 8-12 h after operation (MD = -0.63, 95% CI [-1.11, -0.15], P = 0.01). No significant difference was found for VAS with movement 4-6 h (MD = 0.4, 95% CI [-0.28, 1.08], P = 0.25), and 1 day after operation (MD -0.47, 95% CI [-1.36, 0.43], P = 0.3) (Fig. 5).

## **Opioid drugs consumption**

No significant difference was found for oral morphine equivalents use at 24 h (mg) (MD = 1.4, 95% CI [-1.53, 4.33], P = 0.35) (Fig. 6).

### Nerve block-related complications

The pooled data showed that SSNB group had lower incidence of Horner syndrome (MD = 0.06, 95% CI [0.02, 0.22], P < 0.0001), numb (MD = 0.05, 95% CI [0.01, 0.33],

P = 0.002), subjective dyspnea (MD = 0.4, 95% CI [0.17, 0.95]), hoarseness, (MD = 0.31, 95% CI [0.1, 0.97], P = 0.04). No significant difference was found for vomiting (MD = 0.8, 95% CI [0.38, 1.68], P = 0.56), local tenderness (MD = 0.9, 95% CI [0.27, 3.02], P = 0.87) (Fig. 7).

#### Duration of PACU stay

No significant difference was found for the duration of PACU stay (MD = -1.3, 95% CI [-6.83, 4.23], P = 0.65) (Fig. 8).

### Patient satisfaction

The pooled data showed that no significant difference was found for the rate of patient satisfaction (MD = 3.45, 95% CI [0.67, 17.68], P = 0.14) (Fig. 9).

#### Discussion

We only found two meta-analyses comparing SSNB with ISB. However, there is some difference between our study and the previous two meta-analyses. First, the inclusion standard is different. One meta-analysis by Kay [22] compared SSNB with ISB as well as anesthesia without a nerve block. Another meta-analysis by Hussain [19] included comparison of SSNB plus AXB and ISB. Second, the restriction of the previous meta-analysis to English language publications potentially limits the power obtained with the inclusion of non-English language studies. Third, the previous two studies did not separately evaluate the pain at rest and pain with movement. Under the current background of rapid recovery, patients need to move as soon as possible to achieve quick recovery, so it is essential to evaluate the pain with movement. Fourth, they did not analyze the duration of PACU stay and patient satisfaction. Thus, based on the current studies comparing SSNB with ISB during arthroscopic shoulder surgery, we only compare SSNB with ISB and include English language studies and Chinese RCTs. Moreover, our study added the analysis of pain at rest, pain with movement, duration of PACU stay, and patient satisfaction, which may provide a more exact conclusion and could be a supplement for the previous meta-analysis.

Our data of meta-analysis challenged the purported superiority of ISB over SSNB for shoulder surgery [12, 34, 39, 40]. Interestingly, the rebound phenomenon of increased pain in ISB group in our meta-analysis was not found in the previous two meta-analyses. The postoperative

	Suprascapu	ular nerve	block	Interscale	ene nerve	block		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.2.1 PACU									
Li 2018	1.87	0.62	20	1.89	0.36	20	5.5%	-0.02 [-0.33, 0.29]	+
Singelyn 2004	5.4	2.8	30	1.3	2.5	30	3.3%	4.10 [2.76, 5.44]	
Wang 2019	1.87	0.62	20	1.89	0.36	21	5.5%	-0.02 [-0.33, 0.29]	+
Yao 2019	3.59	2.13	48	2.33	1.64	27	4.4%	1.26 [0.40, 2.12]	_ <b>_</b>
Subtotal (95% CI)			118			98	18.8%	1.05 [0.10, 2.00]	◆
Heterogeneity: Tau <sup>2</sup> = Test for overall effect	= 0.79; Chi <sup>2</sup> = : Z = 2.18 (P =	41.82, df = = 0.03)	= 3 (P < C	0.00001); I <sup>2</sup>	= 93%				
1.2.2 4-6 h									
Li 2018	2.77	0.43	20	3.05	0.93	20	5.3%	-0.28 [-0.73, 0.17]	
Singelyn 2004	3.5	2.5	30	1.3	2.4	30	3.6%	2.20 [0.96, 3.44]	
Wang 2019	2.37	0.43	20	2.05	0.93	21	5.3%	0.32 [-0.12, 0.76]	
Yao 2019	2.89	1.53	48	2.73	1.38	27	4.8%	0.16 [-0.52, 0.84]	+-
Subtotal (95% CI)			118			98	19.0%	0.40 [-0.28, 1.08]	◆
Heterogeneity: Tau <sup>2</sup> = Test for overall effect	= 0.35; Chi <sup>2</sup> = Z = 1.16 (P =	14.59, df = = 0.25)	= 3 (P = C	0.002); I <sup>2</sup> =	79%				
1.2.3 8-12 h									
Jiang 2017	2.9	0.9	24	2.8	1.2	23	5.0%	0.10 [-0.51, 0.71]	+
Li 2018	2.91	0.67	20	3.65	0.718	20	5.3%	-0.74 [-1.17, -0.31]	-
Liu 2020	4.05	1.43	54	5.79	1.5	53	5.1%	-1.74 [-2.30, -1.18]	-
Mai 2019	3.6	1.3	60	4.2	1.5	60	5.2%	-0.60 [-1.10, -0.10]	-
Wang 2019	1.91	0.87	20	2.65	0.52	21	5.3%	-0.74 [-1.18, -0.30]	-
Yao 2019	2.95	1.41	48	2.88	1.62	27	4.7%	0.07 [-0.66, 0.80]	_ <del>_</del>
Subtotal (95% CI)			226			204	30.6%	-0.63 [-1.11, -0.15]	$\bullet$
Heterogeneity: Tau <sup>2</sup> = Test for overall effect	= 0.28; Chi <sup>2</sup> = : Z = 2.59 (P =	24.59, df = = 0.010)	= 5 (P = C	1.0002); I <sup>2</sup> :	= 80%				
1.2.4 1 d									
Auyong 2018	2.8	2.4	60	2.9	2.8	61	4.3%	-0.10 [-1.03, 0.83]	
Jiang 2017	4.3	1.6	24	4.4	1.3	23	4.5%	-0.10 [-0.93, 0.73]	
Li 2018	4.22	1.42	20	4.41	1.31	20	4.5%	-0.19 [-1.04, 0.66]	
Liu 2020	5.21	1.33	54	7.84	1.63	53	5.1%	-2.63 [-3.19, -2.07]	
Singelyn 2004	3.5	1.9	30	3.3	2.2	30	4.0%	0.20 [-0.84, 1.24]	_ <del>_</del>
Wang 2019	2.32	0.62	20	2.41	0.71	20	5.4%	-0.09 [-0.50, 0.32]	*
Yao 2019	3.58	2.15	48	3.76	2.27	27	4.0%	-0.18 [-1.23, 0.87]	
Subtotal (95% CI)			256			234	31.6%	-0.47 [-1.36, 0.43]	•
Heterogeneity: Tau <sup>2</sup> = Test for overall effect	= 1.28; Chi <sup>2</sup> = = Z = 1.03 (P =	61.82, df = = 0.30)	= 6 (P < C	0.00001); I <sup>2</sup>	= 90%				
Total (95% CI)			718			634	100.0%	-0.07 [-0.45, 0.32]	
Heterogeneity: Tau <sup>2</sup> = Test for overall effect Test for subgroup dif	= 0.66; $Chi^2 =$ : Z = 0.34 (P = ferences: $Chi^2$	190.11, df = 0.73) = 13.12, d	= 20 (P ·	< 0.00001) = 0.004), I <sup>2</sup>	$ I^2 = 89\%$ = 77.1%				+ + + + + + + + + + + + + + + + + + +
ia. 5 A forest pla	t diagram	showing	VAS w	ith move	ement T	he por	oled res	ults showed that	SSNB group had higher VAS with movement in
ACU (MD = $1.05$ ,	95% CI [0.1	1, 2], P =	0.03), ł	nowever,	lower V	AS 8-12	2 h afte	r operation (MD	= -0.63, 95% CI $[-1.11, -0.15], P = 0.01).$ No
ignificant differen	ce was fou	ind for V	AS with	n mover	nent 4-6	h (MD	= 0.4.9	95% CL [-0.28, 1.0	18], $P = 0.25$ ) and 1 day after operation (MD $-0.47$ .

95% CI [-1.36, 0.43], P = 0.3)

pain at rest and pain with movement at the individual time points suggested that ISB can provide better pain control that is limited to the PACU stay; however, there is a rebound phenomenon of increased pain in ISB group in the latter time. Compared with the ISB group, the SSNB group provides less pain control in the PACU stay, however, similar or superior pain control in the later time. There may be two reasons for the imperfect early pain control in the SSNB groups. First, the suprascapular nerve rarely has cutaneous innervation, and therefore the SSNB does not provide analgesia for the pain from skin incisions. Second, the suprascapular nerve supplies only 70% of the sensory fibers to the joint and capsule.



**Fig. 6** A forest plot diagram showing opioid drugs consumption. No significant difference was found for oral morphine equivalents use at 24 h (mg) (MD = 1.4, 95% CI [-1.53, 4.33], P = 0.35)

$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Js Ratio 1dom, 95% Cl
Auyong 2015 0 0 60 10 61 2.5% 0.044 [0.00, 0.71] Pertoff 2020 0 24 5 24 2.4% 0.07 [0.00, 0.65] Wang 2019 1 200 8 21 3.5% 0.09 [0.01, 0.77] Va 2019 1 200 6 [0.02, 0.22] Va 2019 1 200 6 [0.02, 0.22] Va 2019 200 0 6 [0.00, 0.4] Va 2019 200 0 24 10 23 5 12 23 50 0.15 [0.02, 0.02] Va 2019 200 1 187 Test for overall effect: Z = 3.12 ( $P = 0.002$ ): $I = 56\%$ Test for overall effect: Z = 3.12 ( $P = 0.002$ ): $I = 56\%$ Test for overall effect: Z = 3.12 ( $P = 0.002$ ): $I = 56\%$ Test for overall effect: Z = 3.12 ( $P = 0.002$ ): $I = 2.51$ ; $I = 3.2$ Va 2019 2 4 4 9 4 4 9 0.18 [0.01, 8.63] Va 2019 2 4 4 9 4 4 9 0.18 [0.01, 0.33] Va 2019 2 4 4 9 0 0.18 [0.0, 0.90] Va 2019 2 4 4 9 0 0.18 [0.0, 0.90] Va 2019 2 4 4 9 0 0.18 [0.0, 0.90] Va 2019 2 4 4 9 0 0.18 [0.0, 0.90] Va 2019 0 4 8 5 47 2.24% 0.07 [0.01, 0.43] Va 2019 0 4 8 5 47 2.24% 0.07 [0.01, 0.42] Va 2019 0 4 8 5 47 2.24% 0.07 [0.01, 0.42] Va 2019 0 2 2 5 2 12 2.4% 0.07 [0.01, 0.42] Va 2019 0 4 8 5 47 2.24% 0.07 [0.00, 1.42] Va 2019 0 2 2 5 2 12 2.4% 0.07 [0.00, 1.42] Va 2019 0 2 2 5 2 12 2.4% 0.07 [0.00, 1.42] Va 2019 0 2 2 5 2 13 13.7% 0.31 [0.10, 0.97] Test for overall effect: Z = 2.01 ( $P = 0.05$ ); $I = 2.02$ ; $I = 1.9\%$ Test for overall effect: Z = 2.01 ( $P = 0.05$ ); $I = 2.25$ ; $I = 2.25$ , $I = 2.25$ , $I = 2.25$ , $I = 2.25$ ; $I = 2.25$ , $I = 2.25$ ; $I = 2.25$ , $I = 2.25$ , $I = 2.25$ ; $I = 2.25$ Va 2019 0 4 4 20 5 21 5.24 0.25 (0.00, 1.42] Va 2019 4 4 20 5 21 5.24 0.25 (0.06, 1.57] Va 2019 4 4 20 5 21 5.24 0.25 (0.06, 1.57] Va 2019 4 4 20 5 21 5.24 0.25 (0.06, 1.57] Va 2019 4 4 20 5 21 5.24 0.25 (0.06, 1.57] Va 2019 4 4 20 5 21 5.24 0.25 (0.06	
Petroff 2020 0 24 5 24 2.4% 0.07 [0.00, 1.39] Total events $1at^2 = 0.00$ ; Ch <sup>2</sup> = 0.31, df = 3 ( $p = 0.96$ ); l <sup>2</sup> = 0% Test for overall effect: Z = 4.18 ( $p < 0.000$ ) 1 122 113 10.3% 0.06 [0.02, 0.22] Total events $1at^2 = 0.00$ ; Ch <sup>2</sup> = 0.31, df = 3 ( $p = 0.96$ ); l <sup>2</sup> = 0% Test for overall effect: Z = 4.18 ( $p < 0.000$ ) 1 142 Numb Addatals 2020 0 67 1 69 2.1% 0.34 (0.01, 8.45] Cas 2019 0 25 25 25 1.5% 0.00 [0.00, 0.02] Correst of coverall effect: Z = 4.18 ( $p < 0.000$ ) 1 142 Numb Addatals 2020 0 647 1 23 5 22 3.5% 0.015 [0.02, 1.45] Coveral effect: Z = 3.12 ( $p - 0.00$ ); l <sup>2</sup> = 56% Test for overall effect: Z = 3.12 ( $p - 0.002$ ) Test for overall effect: Z = 3.12 ( $p - 0.002$ ) Test for overall effect: Z = 2.31; df = 4 ( $p = 0.06$ ); l <sup>2</sup> = 56% Test for overall effect: Z = 2.07 ( $p = 0.61$ ); l <sup>2</sup> = 0% Test for overall effect: Z = 2.07 ( $p = 0.61$ ); l <sup>2</sup> = 0% Test for overall effect: Z = 2.07 ( $p = 0.61$ ); l <sup>2</sup> = 0% Test for overall effect: Z = 2.07 ( $p = 0.61$ ); l <sup>2</sup> = 0% Test for overall effect: Z = 2.07 ( $p = 0.04$ ) 144 Horseness Auyong 2018 8 60 12 61 6.7% 0.63 [0.24, 1.67] Auyong 2018 8 60 12 61 6.7% 0.63 [0.24, 1.67] Petroff 2020 0 24 2 24 2.2% 0.018 [0.01, 0.43] 152 16.2% 0.06 [0.00, 1.42] 153 13.7% 0.31 [0.10, 0.142] 154 Horseness Auyong 2018 8 60 12 61 6.7% 0.63 [0.24, 1.67] Auyong 2018 2 60 9 61 4.9% 0.20 [0.04, 0.96] 144 Horseness Auyong 2018 2 60 9 61 4.9% 0.20 [0.04, 0.96] 142 Horseness Auyong 2018 2 60 9 61 4.9% 0.20 [0.04, 0.96] 143 Vand 2019 0 2 25 22 0.2% 5.54 [0.25, 12.3.08] 142 Vang 2019 2 2 20 0 20 2.2% 5.54 [0.25, 12.3.08] 142 Vang 2019 2 4 2 20 0 20 2.2% 5.54 [0.25, 12.3.08] 143 Vang 2018 2 60 9 61 4.9% 0.20 [0.04, 0.96] 144 Horseness 145 Vandrenets 2 4 145 Vandrenets 2 4 145 Vandrenets 2 4 145 Vandrenets 2 4 146 10 10 4.65 (1.57) 146 10 4.9% 0.20 [0.06, 1.57] 146 10 4.9% 0.28 [0.06, 1.57] 147	-
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	+
Yao 2019 0 0 48 10 47 2.5% 0.044 [0.00, 0.65] Total events 1 152 13 10.3% 0.064 [0.00, 0.62] Total events 1 0.00; Chi <sup>2</sup> = 0.31, df = 3 (P = 0.96); l <sup>2</sup> = 0.64 Reterogenety: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.31, df = 3 (P = 0.96); l <sup>2</sup> = 0.64 Reterogenety: Tau <sup>2</sup> = 0.21, df = 4 (P = 0.06); l <sup>2</sup> = 0.65 Reterogenety: Tau <sup>2</sup> = 0.21, lef = 3 (P = 0.25); l <sup>2</sup> = 0.65 Reterogenety: Tau <sup>2</sup> = 0.32, (ch <sup>2</sup> = 4 (P = 0.06); l <sup>2</sup> = 56 Reterogenety: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.82, df = 3 (P = 0.25); l <sup>2</sup> = 0.65 Reterogenety: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.87, df = 3 (P = 0.25); l <sup>2</sup> = 0.65 Reterogenety: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.87, df = 3 (P = 0.25); l <sup>2</sup> = 0.65 Reterogenety: Tau <sup>2</sup> = 0.33; Ch <sup>2</sup> = 3.71, df = 3 (P = 0.25); l <sup>2</sup> = 0.55 Reterogenety: Tau <sup>2</sup> = 0.32, (Ch <sup>2</sup> = 3, P = 0.25); l <sup>2</sup> = 0.55 Reterogenety: Tau <sup>2</sup> = 0.37, (df = 6 (P = 0.25); l <sup>2</sup> = 0.55 Reterogenety: Tau <sup>2</sup> = 0.07, Ch <sup>2</sup> = 1.82, df = 3 (P = 0.25); l <sup>2</sup> = 0.55 Reterogenety: Tau <sup>2</sup> = 0.37, (df = 3, P = 0.25); l <sup>2</sup> = 0.55 Reterogenety: Tau <sup>2</sup> = 0.33; Ch <sup>2</sup> = 3.71, df = 3 (P = 0.25); l <sup>2</sup> = 0.55 Reterogenety: Tau <sup>2</sup> = 0.33; Ch <sup>2</sup> = 3.71, df = 3 (P = 0.25); l <sup>2</sup> = 0.55 Reterogenety: Tau <sup>2</sup> = 0.38, (Ch <sup>2</sup> = 3.71, df = 3.92, l <sup>2</sup> = 0.55 Reterogenety: Tau <sup>2</sup> = 0.38; Ch <sup>2</sup> = 3.71, df = 3.92, l <sup>2</sup> = 0.55 Reterogenety: Tau <sup>2</sup> = 0.38; Ch <sup>2</sup> = 3.71, df = 3.92, l <sup>2</sup> = 0.55 Reterogenety: Tau <sup>2</sup> = 0.38; Ch <sup>2</sup> = 3.71, df = 3.92, l <sup>2</sup> = 0.55 Reterogenety: Tau <sup>2</sup> = 0.38; Ch <sup>2</sup> = 3.71, df = 3.92, l <sup>2</sup> = 0.55 Reterogenety: Tau <sup>2</sup> = 0.38; Ch <sup>2</sup> = 3.71, df = 3.92, l <sup>2</sup> = 0.55 Reterogenety: Tau <sup>2</sup> = 0.38; Ch <sup>2</sup> = 3.71, df = 3.92, l <sup>2</sup> = 0.55 Reterogenety: Tau <sup>2</sup> = 0.38; Ch <sup>2</sup> = 0.55; l <sup>2</sup> = 0.55 Reterogenety: Tau <sup>2</sup> = 0.58; Ch <sup>2</sup> = 7.55, df = 3.54, lo 2.55 Reterogenety: Tau <sup>2</sup> = 0.58; Ch <sup>2</sup> = 7.55, df = 3.54, lo 2.55, l <sup>2</sup> = 0.56 Reterogenety: Tau <sup>2</sup> = 0.58; Ch <sup>2</sup> = 0.55; l <sup>2</sup> = 0.56 Reterogenety: Tau <sup>2</sup> = 0.58; Ch <sup>2</sup> = 0.55; l <sup>2</sup> = 0.55 Reterogenety: Tau <sup>2</sup> = 0.58; Ch <sup>2</sup> = 0.55; l <sup>2</sup> = 0.55; l <sup>2</sup> = 0.56; l <sup>2</sup> = 0.55; l <sup>2</sup> = 0.55; l <sup>2</sup> = 0.55; l <sup>2</sup> = 0.55; l <sup>2</sup>	-
Subtrail (95% C)) 122 13 10.5% 0.06 [0.02, 0.22] Heterogenetry: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.31, df = 3 (P = 0.96); l <sup>2</sup> = 0% Test for overall effect: $2 = 1.81 \ (P < 0.0001)$ 1.42 Numb Adultal 2020 0 67 1 69 2.1% 0.34 [0.01, 8.45] Co 2019 0 25 25 25 1.5% 0.00 [0.00, 0.02] Covern 2014 1 23 5 2 23.5% 0.15 [0.02, 0.45] Petroff 2020 0 24 11 24 2.4% 0.02 [0.00, 0.44] Petroff 2020 1 46 7 47 3.6% 0.12 [0.01, 0.33] Subtrail (95% C)) 187 13.2% 0.05 [0.01, 0.33] Heterogenetry: Tau <sup>2</sup> = 2.51; Ch <sup>2</sup> = 9.13, df = 4 P = 0.06); l <sup>2</sup> = 56% Test for overall effect: $2 = 3.12 \ (P = 0.02)$ 1.43 Subjective dyspnea Auyong 2019 1 20 3 21 3.2% 0.32 [0.01, 3.32] Heterogenetry: Tau <sup>2</sup> = 0.00; l <sup>3</sup> = 0.61); l <sup>2</sup> = 0% Test for overall effect: $2 = 2.07 \ (P = 0.04)$ 1.44 Mearseness Auyong 2018 8 60 12 61 6.7% 0.63 [0.24, 1.67] Auyong 2018 8 60 12 64 6.7% 0.63 [0.24, 1.67] Auyong 2018 8 60 12 64 6.7% 0.63 [0.24, 1.67] Auyong 2018 8 60 12 64 6.7% 0.63 [0.24, 1.67] Auyong 2018 8 60 12 64 6.7% 0.63 [0.24, 1.67] Auyong 2018 8 60 12 64 6.7% 0.63 [0.24, 1.67] Auyong 2018 8 60 12 64 6.7% 0.63 [0.24, 1.67] Auyong 2018 8 60 12 64 6.7% 0.63 [0.24, 1.67] Auyong 2018 8 60 12 64 6.7% 0.63 [0.24, 1.67] Auyong 2018 8 60 12 64 6.7% 0.63 [0.24, 1.67] Auyong 2018 8 60 12 64 6.7% 0.63 [0.24, 1.67] Auyong 2018 8 60 12 64 6.7% 0.63 [0.24, 1.67] Auyong 2018 8 70 22 20 0 20 2.2% 5.54 [0.25, 12.308] Heterogenetity: Tau <sup>2</sup> = 0.33; Ch <sup>2</sup> = 3.71, df = 3 (P = 0.29); l <sup>2</sup> = 19% Test for overall effect: 2 = 2.01 (P = 0.49) 1.4.5 Vonting Auyong 2018 2 60 9 61 4.9% 0.20 [0.04, 0.96] Lin 2020 2 2 55 72 254 30.04% 0.03 [0.10, 0.57] Total events 8 72 72 6.3% 0.33 [0.16, 1.67] Auyong 2018 2 66 9 61 4.9% 0.20 [0.04, 1.63] Auyong 2018 2 72 72 6.3% 0.33 [0.16, 1.67] Auyong 2018 2 72 72 72 72 72 72 72 72 72 72 72 72 7	
Total events 1 1 $33$ Test for overall effect: $Z = 4.18 (P < 0.9001)$ Addulha 2020 0 67 1 69 2.1% 0.34 (D 01, 8.45) Cos 2019 0 25 25 25 25 1.5% 0.00 (D 00, 0.02) Ovesen 2014 1 23 5 22 3.5% 0.15 (D 02, 10.44) Perroff 2020 0 2.4 11 24 2.4% 0.02 (D 00, 0.44) Perroff 2020 0 2.4 11 24 2.4% 0.02 (D 00, 0.44) Peterogenety: Tau <sup>2</sup> = 2.51; Ch <sup>2</sup> = 9.13, df = 4 (P = 0.06); l <sup>2</sup> = 56% Test for overall effect: $Z = 3.12 (P = 0.002)$ <b>1.4.3 Subjective dyspnea</b> Auyong 2018 5 60 7 61 6.0% 0.70 (D 21, 2.35) Una 2020 0 54 1 23 2.1% 0.32 (D 03, 3.06] Peterogenety: Tau <sup>2</sup> = 2.51; Ch <sup>2</sup> = 9.13, df = 4 (P = 0.06); l <sup>2</sup> = 56% Test for overall effect: $Z = 3.12 (P = 0.002)$ <b>1.4.3 Subjective dyspnea</b> Auyong 2018 5 60 7 61 6.0% 0.70 (D 21, 2.35] Una 2020 0 54 1 23 2.1% 0.32 (D 03, 3.06] Peterogenety: Tau <sup>2</sup> = 2.07 (P = 0.002) <b>1.4.3 Subjective dyspnea</b> Auyong 2018 8 60 12 61 6.7% 0.63 (D 24, 1.67) Peterogenety: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 1.82; df = 3 (P = 0.61); l <sup>2</sup> = 0% Test for overall effect: $Z = 2.07 (P = 0.04)$ <b>1.4.4 Hearsenes1</b> Auyong 2018 8 60 12 61 6.7% 0.63 (D 24, 1.67) Peterof 2020 0 24 2 24 2.2% 0.18 (D 01, 4.04) Wang 2019 0 48 5 47 2.24% 0.07 (D 00, 1.42) Yao 2019 0 48 5 47 2.4% 0.02 (D 04, 0.46) <b>1.4.4 Hearsenes1</b> Auyong 2018 8 60 12 61 6.7% 0.31 (D 01, 0.42) Wang 2019 0 20 5 21 2.4% 0.07 (D 00, 1.42) Wang 2019 0 24 2 24 2.7% 0.31 (D 10, 6.97) <b>1.4.4 Hearsenes1</b> Auyong 2018 8 7 27, df = 3 (P = 0.29); l <sup>2</sup> = 19% Test for overall effect: $Z = 2.01 (P = 0.04)$ <b>1.4.5 Vomiting</b> Auyong 2019 4 20 5 21 5.2% 0.80 (D 18, 1.57] Ovesen 2014 1 23 1 22 2.5% 0.80 (D 18, 1.57] <b>1.4.6 Local tendemess</b> <b>1.4.6 Local tendemenes</b> <b>1.4</b>	
Hetergeneity: Tau' = 0.00; Chi' = 0.31, d' = 3 ( $P = 0.96$ ); h' = 0% Test for overall effect: 2 = 4.18 ( $P < 0.000$ ) <b>14.2 Numb</b> Abdalan 2020 0 67 1 69 2.1% 0.34 ( $D.01, 8.45$ ) Co 2019 0 2 5 25 25 1.5% 0.00 ( $D.00, 0.02$ ) For other 2010 0 0 44 11 24 3.4% 0.02 ( $D.00, 0.02$ ) For other 2010 0 1 44 7 7 47 3.6% 0.12 ( $D.01, 1.031$ ) Subtral (95% C) 1 87 187 187 187 187 187 8.4% 0.05 ( $D.01, 0.031$ ) Total events 2 5 1.2 ( $P = 0.3.05$ 4 4 ( $P = 0.065$ ); h' = 56% Test for overall effect: Z = 3.12 ( $P = 0.3.05$ 4 4 ( $P = 0.065$ ); h' = 56% Test for overall effect: Z = 3.12 ( $P = 0.3.05$ 4 4 ( $P = 0.065$ ); h' = 0.5% Test for overall effect: Z = 3.12 ( $P = 0.61$ ); h' = 0% Test for overall effect: Z = 3.12 ( $P = 0.61$ ); h' = 0% Test for overall effect: Z = 2.07 ( $P = 0.61$ ); h' = 0% Test for overall effect: Z = 2.07 ( $P = 0.61$ ); h' = 0% Test for overall effect: Z = 2.07 ( $P = 0.61$ ); h' = 0% Test for overall effect: Z = 2.01 ( $P = 0.04$ ) <b>14.4 Hoarsenes</b> Avyong 2018 6 60 12 61 6.7% 0.63 ( $D.24, 1.67$ ] Avyong 2018 7 2 24 2.2% 0.18 ( $D.0.0, 0.46$ ] <b>14.4 Hoarsenes</b> Avyong 2018 8 60 12 61 6.7% 0.63 ( $D.24, 1.67$ ] Avyong 2018 7 2 24 2.07 ( $P = 0.04$ ) <b>14.4 Hoarsenes</b> Avyong 2018 2 60 9 61 4.9% 0.20 ( $D.04, 0.61$ , effective 2 2.01 ( $P = 0.04$ ) <b>14.4 Hoarsenes</b> Avyong 2018 2 60 9 61 4.9% 0.20 ( $D.04, 0.61$ , effective 2 2.01 ( $P = 0.04$ ) <b>14.5 Vomitig</b> Avyong 2018 2 60 9 61 4.9% 0.20 ( $D.04, 0.61$ , effective 2 2.01 ( $P = 0.29$ ); h' = 19% Test for overall effect: Z = 2.01 ( $P = 0.29$ ); h' = 19% Test for overall effect: Z = 2.03 ( $P = 0.25$ ); h' = 2.4% Test for overall effect: Z = 2.03 ( $P = 0.25$ ); h' = 2.4% Test for overall effect: Z = 2.03 ( $P = 0.25$ ); h' = 2.4% Test for overall effect: Z = 0.56 ( $P = 0.25$ ; h' = 2.05; h' = 2.4% Test for overall effect: Z = 0.56 ( $P = 0.25$ ; h' = 2.05; h' = 2.4% Test for overall effect: Z = 0.57 ( $P = 0.56$ ) <b>1.45 Local Indenenes</b> AddInh 2020 5 27 0 2.2% 12.2% 12.23 ( $D.66, 2.25, 70$ ] AddInh 2020 5 2.4 6.8 16.3 4.75 5.8 ( $P = 0.25$ ); h' = 2.4% Total events	
1.42 Numb       60 218       0.34 (0.01, 8.45)         Goo 2019       0       25       25       1.5%       0.00 (0.00, 0.02)         Overen 2014       1       23       5       22       5%       0.15 (0.02, 1.45)         Voo 2019       0       24       11       24       2.4%       0.02 (0.00, 0.02)         Subtotal (95% C)       187       1327       666       0.12 (0.01, 1.03)         Total events       2.5       49       187       132.8%       0.05 (0.01, 0.33)         Total events       2.0       0       54       1       53       2.1%       0.32 (0.01, 8.06)         Subtotal (95% CI)       182       182       182       182.1	
Abdalla 2020 0 67 1 69 2.1.% 0.34 (0.01, 8.45) Ovesen 2014 1 23 5 22 3.5% 0.15 (0.02, 1.45) Petroff 2020 0 24 11 24 2.4% 0.02 (0.00, 0.04) Yao 2019 1 48 7 47 3.6% 0.12 (0.01, 1.03) Total events 2 1 49 Heterogeneity: Tar <sup>2</sup> = 2.51; Ch <sup>2</sup> = 9.13, df = 4 (P = 0.06); t <sup>2</sup> = 56% Test for overall effect: 2 = 3.12 (P = 0.02) <b>1.43 Subjective dyspnea</b> Avyong 2018 5 60 7 61 6.0% 0.70 [0.21, 2.35] Ua 2020 0 54 1 33 2.1% 0.32 (0.01, 3.06] Wang 2019 1 2 48 9 47 4.9% 0.18 [0.04, 0.90] <b>Vao 2019</b> 2 48 9 47 4.9% 0.18 [0.04, 0.90] <b>Vao 2019</b> 2 48 9 47 4.9% 0.18 [0.04, 0.90] <b>Vao 2019</b> 2 48 9 47 4.9% 0.18 [0.04, 0.90] <b>Vao 2019</b> 2 48 9 47 4.9% 0.18 [0.04, 0.90] <b>Vao 2019</b> 2 48 9 47 4.9% 0.18 [0.04, 0.90] <b>Vao 2019</b> 2 48 9 47 4.9% 0.18 [0.04, 0.90] <b>Vao 2019</b> 2 48 9 47 4.9% 0.18 [0.04, 0.90] <b>Vao 2019</b> 2 48 9 47 4.9% 0.18 [0.04, 0.90] <b>Vao 2019</b> 2 48 9 47 4.9% 0.18 [0.04, 0.90] <b>Vao 2019</b> 2 48 5 47 2.2% 0.40 [0.17, 0.95] <b>Vao 2019</b> 0 24 5 47 2.2% 0.05 [0.00, 1.42] <b>Vao 2019</b> 0 24 5 47 2.2% 0.05 [0.00, 1.42] <b>Vao 2019</b> 0 24 5 47 2.2% 0.05 [0.00, 1.42] <b>Vao 2019</b> 0 24 5 47 2.2% 0.05 [0.00, 1.42] <b>Vao 2019</b> 0 24 5 47 2.2% 0.31 [0.01, 0.97] <b>Vao 2019</b> 0 24 5 47 2.2% 0.31 [0.01, 0.97] <b>Vao 2019</b> 0 24 5 47 2.2% 0.31 [0.01, 0.97] <b>Vao 2019</b> 0 2 2 20 0 20 2.2% 5.54 [0.25, 123.08] <b>Vao 2019</b> 0 2 2 50 0 20 2.2% 5.54 [0.25, 123.08] <b>Vao 2019</b> 4 20 5 21 5.2% 0.30 [0.06, 1.57] <b>Vao 2019</b> 9 48 7 47 6.3% 1.32 [0.45, 3.54] <b>Vao 2019</b> 9 48 7 47 6.3% 1.32 [0.45, 3.54] <b>Vao 2019</b> 9 48 7 47 6.3% 1.32 [0.45, 3.54] <b>Vao 2019</b> 9 48 7 47 6.3% 1.32 [0.45, 3.54] <b>Vao 2019</b> 9 48 7 47 6.3% 1.32 [0.45, 3.54] <b>Vao 2019</b> 9 48 7 47 6.3% 1.32 [0.45, 3.54] <b>Vao 2019</b> 4 20 5 21 5.2% 0.30 [0.06, 1.57] <b>Vao 2019</b> 4 420 5 21 5.2% 0.30 [0.06, 1.57] <b>Vao 2019</b> 4 48 8 47 5.8% 0.48 [0.13, 3.43] <b>Vao 2019</b> 4 48 8 47 5.8% 0.48 [0.13, 3.43] <b>Vao 2019</b> 4 48 8 47 5.8% 0.46 [0.13, 3.43] <b>Vao 2019</b> 4 48 8 47 5.8% 0.46 [0.13, 3.43] <b>Vao 2019</b> 4 48 8 47 5.8% 0.46 [0.12, 1.59] <b>Vao 2019</b> 4 48 8 47 5.8% 0.46 [0.12, 1.59] <b>Vao 2019</b> 4 4	
Cao 2019 0 25 25 25 25 1.5% 0.00 [0.00, 0.02] Versen 2014 1 23 5 22 3.5% 0.015 [0.02, 1.45] Petroff 2020 0 24 11 24 2.4% 0.02 [0.00, 0.44] Subtotal (95% CD) 187 187 13.2% 0.05 [0.01, 0.33] Subtotal (95% CD) 187 187 13.2% 0.05 [0.01, 0.33] Heterogeneity: Tau" = 2.51; Ch" = 9.13, df = 4 (P = 0.06); l" = 56% Test for overall effect Z = 3.12 (P = 0.06); l" = 56% Test for overall effect Z = 3.12 (P = 0.06); l" = 56% Test for overall effect Z = 0.07 (P = 0.61); l" = 0% Test for overall effect Z = 0.07 (P = 0.61); l" = 0% Test for overall effect Z = 0.17 (P = 0.61); l" = 0% Test for overall effect Z = 0.17 (P = 0.64); l" = 19% Test for overall effect Z = 0.17 (P = 0.29); l" = 19% Test for overall effect Z = 0.17 (P = 0.29); l" = 19% Test for overall effect Z = 0.58 (P = 0.25); l" = 24% Test for overall effect Z = 0.58 (P = 0.25); l" = 24% Test for overall effect Z = 0.58 (P = 0.25); l" = 24% Test for overall effect Z = 0.58 (P = 0.25); l" = 24% Test for overall effect Z = 0.58 (P = 0.25); l" = 19% Test for overall effect Z = 0.58 (P = 0.25); l" = 24% Test for overall effect Z = 0.58 (P = 0.25); l" = 24% Test for overall effect Z = 0.58 (P = 0.25); l" = 24% Test for overall effect Z = 0.58 (P = 0.25); l" = 24% Test for overall effect Z = 0.58 (P = 0.25); l" = 24% Test for overall effect Z = 0.58 (P = 0.25); l" = 24% Test for overall effect Z = 0.58 (P = 0.25); l" = 24% Test for overall effect Z = 0.58 (P = 0.25); l" = 24% Test for overall effect Z = 0.58 (P = 0.25); l" = 24% Test for overall effect Z = 0.58 (P = 0.25); l" = 24% Test for overall effect Z = 0.58 (P = 0.25); l" = 24% Test for overall effect Z = 0.58 (P = 0.25); l" = 24% Test for overall effect Z = 0.58 (P = 0.25); l" = 24% Test for overall effect Z = 0.58 (P = 0.25); l" = 24% Test for overall effect Z = 0.58 (P = 0.25); l" = 25% Test for overall effect Z = 0.58 (P = 0.25); l" = 25% Test for overall effect Z = 0.77 (P = 0.87)	
Oversen 2014 1 23 5 22 3.5% 0.15 $[0.02, 1.45]$ Pretroff 2020 0 24 11 24 2.4% 0.05 $[0.01, 0.33]$ Total events 2 4 49 Heterogenetiy: Tau" = 2.51; Chi <sup>2</sup> = 9.13, df = 4 (P = 0.06); l <sup>2</sup> = 56% Test for overall effect: Z = 3.12 (P = 0.002) <b>1.4.3 Subjective dyspnea</b> Auyong 2018 5 6 60 7 61 6.0% 0.70 $[0.21, 2.35]$ Total events 49 Heterogenetiy: Tau" = 2.51; Chi <sup>2</sup> = 0.002) <b>1.4.3 Subjective dyspnea</b> Auyong 2018 5 6 60 7 61 6.0% 0.70 $[0.21, 2.35]$ Total events 8 2 20 Heterogenetiy: Tau" = 2.51; Chi <sup>2</sup> = 0.002) <b>1.4.3 Subjective dyspnea</b> Auyong 2019 1 1 20 3 21 3.2% 0.32 $[0.01, 3.32]$ Total events 8 2 20 Heterogenetiy: Tau" = 0.00; Chi <sup>2</sup> = 0.61); l <sup>2</sup> = 0.% Test for overall effect: Z = 2.07 (P = 0.04) <b>1.4.4 Hoarseness</b> Auyong 2018 8 60 12 61 6.7% 0.63 $[0.24, 1.67]$ Petroff 2020 0 24 2 24 2.2% 0.18 $[0.01, 4.04]$ Wang 2019 0 20 5 21 2.4% 0.08 $[0.00, 1.48]$ Subtotal (95% Ch) <b>152 153 13.7% 0.31</b> $[0.10, 0.97]$ Total events 8 24 Heterogenetity: Tau" = 0.33; Chi <sup>2</sup> = 3.71, df = 3 (P = 0.29); l <sup>2</sup> = 19% Test for overall effect: Z = 2.01 (P = 0.04) <b>1.4.5 Vomiting</b> Auyong 2018 2 60 9 61 4.9% 0.20 $[0.06, 1.57]$ Oversen 2014 1 23 1 22 3.03 $[0.10, 0.96]$ <b>1.4.5 Vomiting</b> Auyong 2018 2 2 60 9 61 4.9% 0.20 $[0.06, 1.57]$ Oversen 2014 1 23 1 22 3.04 4.4% 2.15 $[0.36, 1.57]$ Diale vents 24 6.05 2.15 2.2% 0.30 $[0.06, 1.57]$ Diale vents 24 6.05 2.15 2.2% 0.30 $[0.06, 1.57]$ Diale vents 24 7 6.3% $1.32 [0.45, 3.38]$ <b>4.5 Stotal (95% Ch) 1.52 153 13.7%</b> <b>5.5 Heterogenetiy:</b> Tau" = 0.23; Chi <sup>2</sup> = 7.87, df = 6 (P = 0.25); l <sup>2</sup> = 2.4% Total events 42 7 6.38 $1.32 [0.45, 3.48]$ <b>4.6 Heterogenetiy:</b> Tau" = 0.23; Chi <sup>2</sup> = 7.87, df = 6 (P = 0.25); l <sup>2</sup> = 2.4% Total events 13 $1.3 1$ $1.3$ <b>1.6 Hoterogenetiy:</b> Tau" = 0.52; Chi <sup>2</sup> = 4.58, df = 3 (P = 0.21); l <sup>2</sup> = 3.5% Total events 13 $1.3$ Heterogenetiy: Tau" = 0.52; Chi <sup>2</sup> = 4.58, df = 3 (P = 0.21); l <sup>2</sup> = 3.5% Total events 13 $1.3$ Heterogenetiy: Tau" = 0.52; Chi <sup>2</sup> = 4.58, df = 3 (P = 0.21); l <sup>2</sup> = 3.5% Total events 13 $1$	
Perform 2020 0 24 11 24 2.4% 0.02 [0.00, 0.44] Subtotal (95% CI) 187 187 187 187 13.2% 0.05 [0.01, 0.33] Subtotal (95% CI) 187 187 187 13.2% 0.05 [0.01, 0.33] Perform 2018 2 49 Heterogeneity: Tau <sup>2</sup> = 2.51; Ch <sup>2</sup> = 9.13, df = 4 ( $P = 0.06$ ); l <sup>2</sup> = 56% Test for overall effect: Z = 3.12 ( $P = 0.002$ ) 1.4.3 Subjective dyspnea Auyong 2018 5 60 7 61 6.0% 0.70 [0.21, 2.35] Liu 2020 0 54 1 53 2.1% 0.32 [0.01, 8.06] Wang 2019 1 200 3 21 3.2% 0.32 [0.01, 8.06] Subtotal (95% CI) 182 182 182 182 182 182. Total events 8 20 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.82, df = 3 ( $P = 0.61$ ); l <sup>2</sup> = 0% Test for overall effect: Z = 0.17 ( $P = 0.64$ ) 1.4.4 Hoarsenes Auyong 2018 8 60 12 61 6.7% 0.63 [0.24, 1.67] Perform 2020 0 24 2 24 2.2% 0.18 [0.01, 4.04] Subtotal (95% CI) 152 153 13.7% 0.31 [0.10, 0.97] Total events 8 24 Heterogeneity: Tau <sup>2</sup> = 0.33; Chi <sup>2</sup> = 3.71, df = 3 ( $P = 0.29$ ); l <sup>2</sup> = 19% Test for overall effect: Z = 2.01 ( $P = 0.04$ ) 1.4.5 Vomitig Auyong 2018 2 60 9 61 4.9% 0.20 [0.04, 0.96] Liu 2020 2 2 54 65 33 4.7% 0.30 [0.06, 1.57] Ovesen 2014 1 23 1 22 2.5% 0.30 [0.06, 1.57] Ovesen 2014 1 23 1 22 2.5% 0.30 [0.06, 1.57] Ovesen 2014 1 23 1 22 2.5% 0.30 [0.06, 1.57] Ovesen 2014 1 23 1 22 2.5% 0.30 [0.06, 1.57] Ovesen 2014 1 23 1 22 2.5% 0.30 [0.08, 1.58] Total events 24 60 9 2.4% 1.22 (15 (0.36, 1.57] Ovesen 2014 3 23 4 20 5 21 5.2% 0.30 [0.18, 3.54] Total events 24 60 9 2.4% 1.22 (1.50, 3.38] Total events 24 60 9 2.4% 1.22 (1.50, 3.38] Total events 24 6.0% 0.58 (1.57, 1.57, 0.58) Abtotal (95% CI) 2 25 25 40 44 0.52 (2.5, 0.30 [0.18, 3.54] Total events 44 8 8 47 5.8% 0.44 [0.12, 1.59] Abtotal (95% CI) 1 668 168 15.6% 0.90 [0.27, 3.02] Total events 13 168 15.6% 0.90 [0.27, 3.02] Total events 13 13 Heterogeneity: Tau <sup>2</sup> = 0.52 (Ch <sup>2</sup> = 4.58, df = 3 ( $P = 0.21$ ); l <sup>2</sup> = 35% Test for overall effect: Z = 0.17 ( $P = 0.87$ )	$\top$
Tab 2.019 1 48 7 47 3.08% 0.12 $[0.01, 1.03]$ Total events 2 1 Total events 2 1 Total events 2 2 49 Heterogeneity: Tau' = 2.51; Ch' = 9.13, df = 4 (P = 0.06); l' = 56% Test for overall effect: Z = 3.12 (P = 0.002) <b>1.4.3 Subjective dyspnea</b> Auyong 2015 5 60 7 61 6.0% 0.70 [0.21, 2.35] Lia 2020 0 54 1 53 2.1% 0.32 [0.03, 3.32] Yao 2019 2 48 9 47 4.9% 0.18 [0.04, 0.90] Subtotal (95% C) 182 182 Total events 8 8 60 12 61 6.7% 0.63 [0.24, 1.67] Heterogeneity: Tau' = 0.00; Ch' = 1.82, df = 3 (P = 0.61); l' = 0% Test for overall effect: Z = 2.07 (P = 0.04) <b>1.4.4 Hoarseness</b> Auyong 2018 8 60 12 61 6.7% 0.63 [0.24, 1.67] Heterogeneity: Tau' = 0.00; Ch' = 3.71, df = 3 (P = 0.29); l' = 19% Total events 8 8 24 Heterogeneity: Tau' = 0.33; Ch' = 3.71, df = 3 (P = 0.29); l' = 19% Test for overall effect: Z = 2.01 (P = 0.04) <b>1.4.5 Vonting</b> Auyong 2018 2 60 9 61 4.9% 0.20 [0.04, 0.96] Lia 2020 2 2 54 6 53 4.7% 0.30 [10.6, 1.57] Mang 2019 0 2 2 52 153 13.7% 0.31 [0.106, 1.57] Mang 2019 4 20 5 21 5.2% 0.30 [1.06, 1.57] Mang 2019 4 20 5 21 5.2% 0.30 [1.06, 1.57] Mang 2019 4 20 5 21 5.2% 0.30 [1.06, 1.57] Mang 2019 4 4 20 5 21 5.2% 0.30 [1.06, 1.57] Mang 2019 4 4 20 5 21 5.2% 0.30 [1.06, 1.57] Mang 2019 4 4 20 5 21 5.2% 0.30 [1.06, 1.57] Mang 2019 4 4 20 5 21 5.2% 0.30 [1.06, 1.57] Mang 2019 4 4 20 5 21 5.2% 0.30 [1.06, 1.57] Mang 2019 4 4 20 5 21 5.2% 0.30 [1.06, 1.57] Mang 2019 4 4 20 5 21 5.2% 0.30 [1.06, 1.57] Mang 2019 4 4 20 5 21 5.2% 0.30 [1.06, 1.57] Mang 2019 4 4 20 5 21 5.2% 0.30 [1.06, 1.57] Mang 2019 4 4 20 5 21 5.2% 0.30 [1.0, 0.3, 1.3] Mang 2019 4 4 20 5 21 5.2% 0.30 [1.0, 0.3, 1.43] Mang 2019 4 4 20 5 21 5.2% 0.30 [1.0, 0.3, 1.43] Mang 2019 4 4 20 5 21 5.2% 0.30 [1.0, 0.3, 1.43] Mang 2019 4 4 48 8 47 5.8% 0.44 [0.12, 1.59] Mang 2019 4 4 8 8 47 5.8% 0.44 [0.12, 1.59] Meterogeneity: Tau' = 0.23; Ch' = 7.87, df = 6 (P = 0.25); l' = 24% Test for overall effect: Z = 0.17 (P = 0.87) Heterogeneity: Tau' = 0.23; Ch' = 7.87, df = 6 (P = 0.25); l' = 35\% Total events 13 168 15.6%	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	
$\begin{aligned} 1.43 \text{ events} & Tav^2 = 2.51; \ Ch^2 = 9.13, \ df = 4 \ (P = 0.06); \ l^2 = 56\% \\ \text{Test for overall effect: $Z = 3.12 \ (P = 0.002) \end{aligned}$ $\begin{aligned} 1.43 \text{ Subjective dyspnea} \\ \text{Auyong 2018} & 5 & 60 & 7 & 61 & 6.0\% & 0.70 \ [0.21, 2.35] \\ \text{Lu 2020} & 0 & 54 & 1 & 53 & 2.1\% & 0.32 \ [0.01, 8.06] \\ \text{Wang 2019} & 1 & 20 & 3 & 21 & 3.2\% & 0.32 \ [0.03, 3.32] \end{aligned}$ $\begin{aligned} \text{Total events} & 8 & 20 \\ \text{Heterogeneity; Tav^2 = 0.00; Ch^2 = 1.82, \ df = 3 \ (P = 0.61); \ l^2 = 0\% \\ \text{Test for overall effect: $Z = 2.07 \ (P = 0.04) \end{aligned}$ $\begin{aligned} 1.44 \ \text{Hoarseness} \\ \text{Auyong 2018} & 8 & 60 & 12 & 61 & 6.7\% & 0.63 \ [0.24, 1.67] \\ \text{Evertof 2020} & 0 & 24 & 2 & 24 & 2.2\% & 0.18 \ [0.00, 1.42] \\ \text{Wang 2019} & 0 & 20 & 5 & 21 & 2.4\% & 0.07 \ [0.00, 1.42] \\ \text{Wang 2019} & 0 & 20 & 5 & 21 & 2.4\% & 0.07 \ [0.00, 1.42] \\ \text{Wang 2019} & 0 & 48 & 5 & 47 & 2.4\% & 0.08 \ [0.00, 1.42] \\ \text{Wang 2019} & 0 & 48 & 5 & 47 & 2.4\% & 0.08 \ [0.00, 1.42] \\ \text{Wang 2019} & 0 & 48 & 5 & 47 & 2.4\% & 0.08 \ [0.00, 1.42] \\ \text{Wang 2019} & 0 & 48 & 5 & 47 & 2.4\% & 0.31 \ [0.10, 0.97] \\ \text{Test for overall effect: $Z = 2.01 \ (P = 0.04) \\ \text{L4.5 Vomiting} \\ \text{Auyong 2018} & 2 & 60 & 9 & 61 & 4.9\% & 0.20 \ [0.04, 0.96] \\ \text{Lin 2020} & 2 & 54 & 6 & 53 & 47.\% & 0.30 \ [0.06, 1.57] \\ \text{Ovesen 2014} & 1 & 23 & 1 & 22 & 2.5\% & 0.95 \ [0.46, 1.627] \\ \text{Total events} & 24 \\ Heterogeneity; Tau^2 = 0.38 \ (Ch = 2.5\% \ 1.22 \ 0.5\% \ 1.25 \ 1.22 \ 0.5\% \ 1.22 \ 0.5\% \ 1.22 \ 0.5\% \ 1.22 \ 0.5\% \ 1.22 \ 0.5\% \ 1.22 \ 0.5\% \ 1.22 \ 0.5\% \ 1.22 \ 0.5\% \ 1.22 \ 0.5\% \ 1.25 \ 1.25 \$	
<b>1.4.3 Subjective dyspnea</b> Auyong 2018 5 60 7 61 6.0% 0.70 [0.21, 2.35] Lu 2020 0 54 1 33 2.1% 0.32 [0.01, 8.06] Wang 2019 1 2 48 9 47 4.9% 0.18 [0.04, 0.90] <b>Subtoal (95% CI)</b> 182 182 16.2% 0.40 [0.17, 0.95] Total events 8 20 Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 1.82, df = 3 ( $P = 0.61$ ); l <sup>2</sup> = 0% Test for overall effect: 2 = 2.07 ( $P = 0.04$ ) <b>1.4.4 Hoarseness</b> Auyong 2018 8 60 12 61 6.7% 0.63 [0.24, 1.67] Petroff 2020 0 24 2 24 2.2% 0.18 [0.01, 4.04] Wang 2019 0 20 5 21 2.4% 0.07 [0.00, 1.42] Yao 2019 0 48 5 47 2.4% 0.08 [0.00, 1.42] Yao 2019 0 48 5 47 2.4% 0.08 [0.00, 1.42] Yao 2019 0 48 5 47 2.4% 0.08 [0.00, 1.42] Total events 18 24 Heterogeneity: Tau <sup>2</sup> = 0.37; df = 3 ( $P = 0.29$ ); l <sup>2</sup> = 19% Test for overall effect: Z = 2.01 ( $P = 0.04$ ) <b>1.4.5 Vomiting</b> Auyong 2018 2 60 9 61 4.9% 0.20 [0.04, 0.96] Liu 2020 2 2 54 6 53 4.7% 0.38 [0.06, 1.57] Owesen 2014 1 23 1 22 2.5% 0.95 [0.06, 1.627] Total events 24 50 23 0 4.4% 2.15 [0.36, 1.276] Wang 2019 9 48 7 47 6.3% 1.32 [0.45, 3.89] Total events 24 30 Heterogeneity: Tau <sup>2</sup> = 0.32; Ch <sup>2</sup> = .787, df = 6 ( $P = 0.25$ ); l <sup>2</sup> = 24% Test for overall effect: Z = 0.58 ( $P = 0.56$ ) <b>1.4.6 Local tenderness</b> Abdala 2020 5 21 5.2% 0.48 [0.163, 1.3, 43] Singelyn 2004 1 3 20 1 30 2.6% 1.00 [0.06, 1.57] Owesen 2014 1 23 1 22 5.5% 0.80 [0.38, 1.68] <b>4.64 0.68 [0.13, 3.43]</b> <b>4.64 0.68 [0.13, 3.43]</b> <b>5.754 30.4% 0.80 [0.38, 1.68]</b> <b>4.75 (SCI)</b> 2.55 ( $P = 0.56$ ) <b>1.4.6 Local tenderness</b> Abdala 2020 5 2.7% 0.4% 0.24 [0.24, 5.38] <b>4.75 (SCI)</b> 2.6% 0.90 [0.27, 3.02] <b>5.754 30.4% 0.80 [0.38, 1.68]</b> <b>5.754 30.4% 0.80 [0.38, 1.68]</b> <b>5.754 30.4% 0.80 [0.38, 1.68]</b> <b>5.754 30.4% 0.90 [0.27, 3.02]</b> <b>5.754 30.4% 0.90 [0.27,</b>	
Auyong 2018 5 60 7 61 6.0% 0.7 0 [0,21, 2, 35] Li 2020 0 54 1 53 2, 1/4 0.32 [0,01, 8, 66] Avang 2019 1 2 0 3 21 3, 2/4 0.32 [0,03, 3, 32] Fotal events 8 20 Heterogeneity: Tau <sup>2</sup> = 0.0; Chi <sup>2</sup> = 1.82, df = 3 (P = 0.61); l <sup>2</sup> = 0% Test for overall effect: Z = 2.07 (P = 0.04) <b>1.4.4 Hoarseness</b> Auyong 2018 8 60 12 61 6.7% 0.63 [0,24, 1.67] Auyong 2018 8 60 12 61 6.7% 0.63 [0,24, 1.67] Avang 2019 0 24 2 24 2.2% 0.18 [0,01, 4.04] Avang 2019 0 20 5 21 2.2.4% 0.07 [0,00, 1.42] Fotal events 8 24 Heterogeneity: Tau <sup>2</sup> = 0.33; Chi <sup>2</sup> = 3.71, df = 3 (P = 0.29); l <sup>2</sup> = 19% Test for overall effect: Z = 2.01 (P = 0.04) <b>1.4.5 Vomiting</b> Auyong 2018 2 60 9 61 4.9% 0.20 [0.04, 0.96] Li 2020 2 2 54 6 53 4.7% 0.31 [0.10, 0.97] <b>1.4.5 Vomiting</b> Auyong 2018 2 60 9 61 4.9% 0.20 [0.04, 0.96] Li 2020 2 2 54 6 53 4.7% 0.30 [0.06, 1.57] Desen 2014 1 23 1 22 2.2% 0.95 [0.06, 1.57] Desen 2014 1 23 1 22 2.2% 0.95 [0.06, 1.57] Desen 2014 1 23 1 22 2.2% 0.95 [0.06, 1.57] Desen 2014 1 23 1 22 2.2% 0.95 [0.06, 1.57] Desen 2014 1 23 1 22 2.2% 0.95 [0.06, 1.57] Desen 2014 1 23 1 22 2.2% 0.95 [0.06, 1.57] Desen 2014 1 23 1 22 0.3 4.4% 2.21 55 (0.36, 10.24, 0.6] Total events 24 30 Test for overall effect: Z = 0.58 (P = 0.25); l <sup>2</sup> = 24% Test for overall effect: Z = 0.58 (P = 0.25); l <sup>2</sup> = 24% Test for overall effect: Z = 0.58 (P = 0.25); l <sup>2</sup> = 24% Test for overall effect: Z = 0.58 (P = 0.25); l <sup>2</sup> = 24% Test for overall effect: Z = 0.58 (P = 0.25); l <sup>2</sup> = 24% Test for overall effect: Z = 0.58 (P = 0.25); l <sup>2</sup> = 24% Test for overall effect: Z = 0.58 (P = 0.25); l <sup>2</sup> = 24% Test for overall effect: Z = 0.58 (P = 0.25); l <sup>2</sup> = 24% Test for overall effect: Z = 0.58 (P = 0.25); l <sup>2</sup> = 24% Test for overall effect: Z = 0.58 (P = 0.25); l <sup>2</sup> = 24% Test for overall effect: Z = 0.58 (P = 0.25); l <sup>2</sup> = 24% Test for overall effect: Z = 0.58 (P = 0.25); l <sup>2</sup> = 25% Test for overall effect: Z = 0.57 (Chi <sup>2</sup> = 4.58, df = 3 (P = 0.21); l <sup>2</sup> = 35% Test for overall effect: Z = 0.17 (P = 0.87)	
Li $2020$ 0 54 1 53 2.1% 0.32 [0.01, 8.06] Wang 2019 1 2 48 9 47 4.9% 0.18 [0.04, 0.90] Subtotal (95% CI) 182 182 16.2% 0.40 [0.17, 0.95] Total events 8 20 Test for overall effect: Z = 2.07 (P = 0.04) 1.4.4 Hoarseness Auyong 2018 8 60 12 61 6.7% 0.63 [0.24, 1.67] Perforf 2020 0 24 2 24 2.2% 0.18 [0.01, 4.04] Wang 2019 0 20 5 21 2.4% 0.07 [0.00, 1.42] Cao 2019 0 20 5 21 2.4% 0.07 [0.00, 1.42] Subtotal (95% CI) 152 153 13.7% 0.31 [0.10, 0.97] Fotal events 8 24 Heterogeneity: Tau <sup>2</sup> = 0.33; Chi <sup>2</sup> = 3.71, df = 3 (P = 0.29); l <sup>2</sup> = 19% Fest for overall effect: Z = 2.01 (P = 0.04) 1.4.5 Vomiting Auyong 2018 2 60 9 61 4.9% 0.20 [0.04, 0.96] Jun 2020 2 2 54 6 53 4.7% 0.30 [0.06, 1.57] Useen 2014 1 23 1 22 2.5% 0.95 [0.06, 16.27] Jung 2019 9 48 7 47 6.3% 0.30 [0.06, 1.57] Jung 2019 9 48 7 47 6.3% 0.30 [0.06, 1.57] Jung 2019 9 48 7 47 6.3% 0.30 [0.35, 14] Fotal events 24 Test for overall effect: Z = 0.58 (P = 0.25); l <sup>2</sup> = 24% Test for overall effect: Z = 0.58 (P = 0.25); l <sup>2</sup> = 24% Test for overall effect: Z = 0.58 (P = 0.25); l <sup>2</sup> = 24% Test for overall effect: Z = 0.58 (P = 0.25); l <sup>2</sup> = 24% Test for overall effect: Z = 0.58 (P = 0.25); l <sup>2</sup> = 24% Test for overall effect: Z = 0.58 (P = 0.56) 1.4.6 Local tenderness Modalla 2020 5 67 0 69 2.4% 1.2.23 [0.66, 225.70] Juseen 2014 1 30 1 30 2.6% 1.00 [0.06, 15.77] Jung 2019 4 422 4.8% 0.68 [0.13, 3.43] Total events 24 30 Value 20 5 67 0 69 2.4% 1.2.23 [0.66, 225.70] Juseen 2014 1 30 1 30 2.6% 1.00 [0.06, 15.75] Justotal (95% CI) 168 168 15.6% 0.90 [0.27, 3.02] Total events 124 Test for overall effect: Z = 0.58 (F = 0.56) 1.4.6 Local tenderness Modalla 2020 5 67 0 69 2.4% 12.23 [0.66, 225.70] Justotal (95% CI) 168 13 3 Test are overall effect: Z = 0.17 (P = 0.87) Total events 13 13 Test e	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	
Tab 2019 2 4 88 9 47 4.9% 0.18 [0.04, 0.90] Total events 8 2 20 Heterogeneity: Tau <sup>2</sup> = 0.0; Chi <sup>2</sup> = 1.82, df = 3 ( $P = 0.61$ ); $i2 = 0\%$ Test for overall effect: $Z = 2.07$ ( $P = 0.04$ ) <b>1.4.4 Hoarseness</b> Auyong 2018 8 60 12 61 6.7% 0.63 [0.24, 1.67] Petroff 2020 0 24 2 24 2.2% 0.18 [0.01, 4.04] Wang 2019 0 20 5 21 2.4% 0.07 [0.00, 1.42] Yao 2019 0 48 5 47 2.4% 0.08 [0.00, 1.42] Yao 2019 0 152 153 13.7% 0.31 [0.10, 0.97] Total events 8 74 Heterogeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 3.71, df = 3 ( $P = 0.29$ ); $i2 = 19\%$ Test for overall effect: $Z = 2.01$ ( $P = 0.04$ ) <b>1.4.5 Vomitig</b> Auyong 2018 2 60 9 61 4.9% 0.20 [0.04, 0.96] Lim 2020 2 2 20 0 20 2.2% 5.54 [0.25, 123.08] Lim 2020 2 2 54 6 53 4.7% 0.30 [0.06, 1.57] Doesen 2014 1 23 1 22 2.5% 0.95 [0.06, 1.62,7] Doesen 2014 1 23 1 22 2.5% 0.95 [0.06, 1.62,7] Displety 2004 4 30 2 30 4.4% 2.15 [0.36, 12.76] Wang 2019 9 48 7 47 6.3% 1.32 [0.45, 3.89] Subtotal (95% CI) 255 254 30.4% 0.80 [0.38, 1.68] Total events 24 30 Heterogeneity: Tau <sup>2</sup> = 0.53; Chi <sup>2</sup> = 3.71, df = 6 ( $P = 0.25$ ); $i2 = 24\%$ Test for overall effect: $Z = 0.58$ ( $P = 0.56$ ) <b>1.4.6 Local tenderness</b> Abdalla 2020 5 67 0 69 2.4% 12.23 [0.66, 225.70] Doesen 2014 3 22 4.8% 0.68 [0.13, 3.43] Doesen 2014 3 23 4 22 4.8% 0.64 [0.12, 1.59] <b>1.4.6 Local tenderness</b> Abdalla 2020 5 67 0 69 2.4% 12.23 [0.66, 225.70] Doesen 2014 3 23 4 22 4.8% 0.64 [0.12, 1.59] <b>1.4.6 Local tenderness</b> Abdalla 2020 5 67 0 69 2.4% 12.23 [0.66, 225.70] Doesen 2014 3 23 4 22 4.8% 0.64 [0.13, 3.43] Displety 2004 1 30 1 30 2.6% 1.00 [0.06, 1.6, 76] Doesen 2014 3 2.3 4 2.2 4.8% 0.64 [0.12, 1.59] Doesen 2014 3 2.3 4 2.2 4.8% 0.64 [0.12, 1.59] Displety 2004 1 30 1 30 2.6% 1.00 [0.06, 1.6, 76] Total events 13 13 Heterogeneity: Tau <sup>2</sup> = 0.52; Chi <sup>2</sup> = 4.58, df = 3 ( $P = 0.21$ ); $i2 = 35\%$ Fest for overall effect: $Z = 0.17$ ( $P = 0.87$ )	
Total events 8 20 Total events 22 20 Test for overall effect: $Z = 2.07 (P = 0.61)$ ; $I^2 = 0\%$ Test for overall effect: $Z = 2.07 (P = 0.04)$ <b>1.4.4 Hoarseness</b> Auyong 2018 8 60 12 61 6.7% 0.63 [0.24, 1.67] Petroff 2020 0 24 2 24 2.2% 0.18 [0.01, 4.04] Wang 2019 0 48 5 47 2.4% 0.07 [0.00, 1.42] Yao 2019 0 48 5 47 2.4% 0.08 [0.00, 1.48] Subtotal (95% CI) 152 153 13.7% 0.31 [0.10, 0.97] Total events 8 224 Test for overall effect: $Z = 2.01 (P = 0.29)$ ; $I^2 = 19\%$ Test for overall effect: $Z = 2.01 (P = 0.29)$ ; $I^2 = 19\%$ Test for overall effect: $Z = 2.01 (P = 0.04)$ <b>1.4.5 Vomiting</b> Auyong 2018 2 60 9 61 4.9% 0.20 [0.04, 0.96] I.u 2020 2 2 54 6 53 4.7% 0.30 [0.06, 1.57] Divesen 2014 1 23 1 22 2.5% 0.95 [0.06, 16.27] Divesen 2014 1 23 1 22 2.5% 0.95 [0.06, 16.27] Divesen 2014 1 23 1 22 2.5% 0.80 [0.18, 3.54] Avag 2019 4 20 5 21 5.2% 0.80 [0.18, 3.54] Fotal events 24 30 Test for overall effect: $Z = 0.23$ ; Chi <sup>2</sup> = 7.87, df = 6 (P = 0.25); I <sup>2</sup> = 24% Test for overall effect: $Z = 0.23$ ; Chi <sup>2</sup> = 7.87, df = 6 (P = 0.25); I <sup>2</sup> = 24% Test for overall effect: $Z = 0.58 (P = 0.56)$ <b>1.4.6 Local tenderness</b> Abdallah 2020 5 67 0 69 2.4% 12.23 [0.66, 225.70] Divesen 2014 1 30 1 30 2.6% 1.00 [0.06, 16.76] Abdallah 2020 5 67 0 69 2.4% 12.23 [0.66, 225.70] Divesen 2014 1 30 1 30 2.6% 0.90 [0.27, 3.02] Total events 13 13 Total events 13 13 Tot	- -
1.4.4 Hoarseness         Auyong 2018       8       60       12       61       6.7%       0.63       [0.24, 1.67]         Petroff 2020       0       24       2       24       2.2%       0.18       [10.01, 4.04]         Wang 2019       0       20       5       21       2.4%       0.07       [10.01, 1.40]         Yao 2019       0       48       5       47       2.4%       0.08       [0.00, 1.42]         Yao 2019       0       48       5       47       2.4%       0.08       [0.00, 1.42]         Yao 2019       0       48       5       47       2.4%       0.08       [0.00, 1.42]         Total events       8       24         Heterogeneity: Tau <sup>2</sup> = 0.33; Chi <sup>2</sup> = 3.71, df = 3 (P = 0.29); I <sup>2</sup> = 19%       Test for overall effect: Z = 2.01 (P = 0.04)       1       20       1       2.5       153       13.7%       0.31 [0.10, 0.97]       1         1.4.5 Vomiting       4       4       30       2       0.4%       0.20 [0.04, 0.96]       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1	
Auyong 2018 8 60 12 61 6.7% 0.63 [0.24, 1.67] Petroff 2020 0 24 2 24 2.2% 0.18 [0.01, 4.04] Nang 2019 0 20 5 21 2.4% 0.07 [0.00, 1.42] (ao 2019 0 48 5 47 2.4% 0.08 [0.00, 1.43] <b>152</b> 153 13.7% 0.31 [0.10, 0.97] Total events 8 24 Peterogeneity: Tau <sup>2</sup> = 0.33; Chi <sup>2</sup> = 3.71, df = 3 (P = 0.29); l <sup>2</sup> = 19% Fest for overall effect: Z = 2.01 (P = 0.04) <b>1.4.5 Vomiting</b> Auyong 2018 2 60 9 61 4.9% 0.20 [0.04, 0.96] 	
Petroff 2020 0 24 2 24 2.2% 0.18 [0.01, 4.04] Wang 2019 0 20 5 21 2.4% 0.07 [0.00, 1.42] Subtotal (95% CI) 152 153 13.7% 0.31 [0.10, 0.97] Total events 8 24 Heterogeneity: Tau <sup>2</sup> = 0.33; Ch <sup>2</sup> = 3.71, df = 3 (P = 0.29); l <sup>2</sup> = 19% Test for overall effect: Z = 2.01 (P = 0.04) 1.4.5 Vomiting Auyong 2018 2 60 9 61 4.9% 0.20 [0.04, 0.96] Lim 2020 2 2 20 0 20 2.2% 5.54 [0.25, 123.08] Lim 2020 2 2 54 6 53 4.7% 0.30 [0.06, 1.57] Outes 2014 1 23 1 22 2.5% 0.95 [0.06, 16.27] Outes 2019 4 20 5 21 5.2% 0.80 [0.18, 3.54] Yang 2019 4 20 5 21 5.2% 0.80 [0.18, 3.54] Total events 24 30 Total events 24 30 Heterogeneity: Tau <sup>2</sup> = 0.23; Chi <sup>2</sup> = 7.87, df = 6 (P = 0.25); l <sup>2</sup> = 24% Test for overall effect: Z = 0.58 (P = 0.56) 1.4.6 Local tenderness Abdallah 2020 5 67 0 69 2.4% 12.23 [0.66, 225.70] Ouesen 2014 3 23 4 22 4.8% 0.68 [0.13, 3.43] Singlelyn 2004 1 30 1 30 2.6% 1.00 [0.06, 16.67] Duesen 2014 3 23 4 22 4.8% 0.68 [0.13, 3.43] Singlelyn 2004 1 30 1 30 2.6% 1.00 [0.06, 16.67] Duesen 2014 3 23 4 22 4.8% 0.68 [0.13, 3.43] Singlelyn 2004 1 30 1 30 2.6% 1.00 [0.06, 16.67] Duesen 2014 3 23 4 22 4.8% 0.68 [0.13, 3.43] Singlelyn 2004 1 30 1 30 2.6% 1.00 [0.06, 16.76] Duesen 2014 3 23 4 22 4.8% 0.68 [0.13, 3.43] Singlelyn 2004 1 30 1 30 2.6% 1.00 [0.06, 16.76] Total events 13 13 Heterogeneity: Tau <sup>2</sup> = 0.52; Chi <sup>2</sup> = 4.58, df = 3 (P = 0.21); l <sup>2</sup> = 35% Test for overall effect: Z = 0.17 (P = 0.87)	<b>_</b>
Wang 20190205212.4%0.07 [0.00, 1.42]fao 20190485472.4%0.08 [0.00, 1.48]fao 20190485472.4%0.03 [0.10, 0.97]Total events824Heterogeneity: Tau <sup>2</sup> = 0.33; Chi <sup>2</sup> = 3.71, df = 3 (P = 0.29); l <sup>2</sup> = 19%Fest for overall effect: Z = 2.01 (P = 0.04)L4.5 VomitingAuyong 20182609614.9%0.20 [0.04, 0.96].im 20202200202.2%5.54 [0.25, 123.08].iu 20202546534.7%0.30 [0.06, 16.27]Deseen 20141231222.5%0.05 [0.06, 16.27]Singelyn 20044302304.4%2.15 [0.36, 12.76]Vang 20199487476.3%1.32 [0.45, 3.89]Subtotal (95% CI)25525430.4%0.80 [0.38, 1.68]Cola levents24302304.4%Fest for overall effect: Z = 0.58 (P = 0.56)1301.302.6%1.00 [0.06, 16.76]L4.6 Local tenderness48475.8%0.44 [0.12, 1.59]Singelyn 20041301302.6%0.090 [0.27, 3.02]Cotal (95% CI)16816815.6%0.90 [0.27, 3.02]Desen 201413313Heterogeneity: Tau <sup>2</sup> = 0.52; Chi <sup>2</sup> = 4.58, df = 3 (P = 0.21); l <sup>2</sup> = 35%13Fest for overall effect: Z =	
aa 2019       0       48       5       47       2.4%       0.08 [0.00, 1.48]         ubtotal (95% CI)       152       153       13.7%       0.31 [0.10, 0.97]         ordal events       8       24         teterogeneity: Tau <sup>2</sup> = 0.33; Chi <sup>2</sup> = 3.71, df = 3 (P = 0.29); l <sup>2</sup> = 19%         est for overall effect: Z = 2.01 (P = 0.04)         L4.5 Vomiting         Nuyong 2018       2       60       9       61       4.9%       0.20 [0.04, 0.96]         in 2020       2       20       0       20.2.2%       5.54 [0.25, 123.08]       -         Divesen 2014       1       23       1       22       2.5%       0.95 [0.06, 16.27]       -         Vang 2019       4       30       2       30       4.4%       2.15 [0.36, 12.76]       -         Vang 2019       9       48       7       47       6.3%       1.32 [0.45, 3.89]       -         valbtotal (95% CI)       255       254       30.4%       0.80 [0.38, 1.68]       -         veterogeneity: Tau <sup>2</sup> = 0.23; Chi <sup>2</sup> = 7.87, df = 6 (P = 0.25); l <sup>2</sup> = 24%       est for overall effect: Z = 0.58 (P = 0.56)       -       -         L4.6 Local tenderness       -       -       -       -       -       -	<del></del>
ubtotal (95% Cl)       152       153       13.7%       0.31 [0.10, 0.97]         otal events       8       24         leterogeneity: Tau <sup>2</sup> = 0.33; Chi <sup>2</sup> = 3.71, df = 3 (P = 0.29); l <sup>2</sup> = 19%         est for overall effect: Z = 2.01 (P = 0.04)         .4.5 Vomiting         uuyong 2018       2       60       9       61       4.9%       0.20 [0.04, 0.96]	<del></del>
Total events 8 24 leterogeneity: $Tau^2 = 0.33$ ; $Chi^2 = 3.71$ , $df = 3$ ( $P = 0.29$ ); $l^2 = 19\%$ lest for overall effect: $Z = 2.01$ ( $P = 0.04$ ) L4.5 Vomiting Usyong 2018 2 60 9 61 4.9% 0.20 [0.04, 0.96] im 2020 2 200 0 20 2.2% 5.54 [0.25, 123.08] im 2020 2 2 54 6 53 4.7% 0.30 [0.06, 16.27] ingelyn 2004 4 30 2 30 4.4% 2.15 [0.36, 12.76] ingelyn 2004 4 30 2 30 4.4% 2.15 [0.36, 12.76] ingelyn 2004 4 30 2 30 4.4% 2.15 [0.36, 12.76] ingelyn 2019 9 48 7 47 6.3% 0.80 [0.18, 3.54] inductal (95% CI) 255 254 30.4% 0.80 [0.38, 1.68] intercogeneity: $Tau^2 = 0.23$ ; $Chi^2 = 7.87$ , $df = 6$ ( $P = 0.25$ ); $l^2 = 24\%$ rest for overall effect: $Z = 0.58$ ( $P = 0.56$ ) L4.6 Local tenderness total events 24 30 42 4.8% 0.68 [0.13, 3.43] ingelyn 2004 1 30 1 30 2.6% 1.00 [0.06, 16.76] ingelyn 2004 1 30 1 30 2.6% 0.40 [0.16, 1.576] ingelyn 2004 1 30 1 30 2.6% 0.40 [0.06, 16.76] ingelyn 2004 1 30 1 30 2.6% 0.40 [0.06, 16.76] ingelyn 2004 1 30 1 30 2.6% 0.40 [0.06, 16.76] ingelyn 2004 1 30 1 30 2.6% 0.40 [0.06, 16.76] ingelyn 2004 1 30 1 30 2.6% 0.40 [0.06, 16.76] ingelyn 2004 1 30 1 30 2.6% 0.40 [0.06, 16.76] ingelyn 2004 1 30 1 30 2.6% 0.40 [0.06, 16.76] ingelyn 2004 1 30 1 30 2.6% 0.40 [0.06, 16.76] ingelyn 2004 1 30 1 30 2.6% 0.40 [0.02, 1.59] inductal (95% CI) 168 168 15.6% 0.90 [0.27, 3.02] inductal (95% CI) 168 168 15.6% 0.90 [0.27, 3.02] inductal (95% CI) 168 168 15.6% 0.90 [0.27, 3.02] inductal effect: $Z = 0.17$ ( $P = 0.87$ )	-
Heterogeneity: Tau <sup>2</sup> = 0.33; Chi <sup>2</sup> = 3.71, df = 3 (P = 0.29); l <sup>2</sup> = 19% Test for overall effect: Z = 2.01 (P = 0.04) L4.5 Vomiting Auyong 2018 2 60 9 61 4.9% 0.20 [0.04, 0.96] in 2020 2 2 00 0 20 2.2% 5.54 [0.25, 123.08] in 2020 2 2 54 6 53 4.7% 0.30 [0.06, 1.57] Divesen 2014 1 23 1 22 2.5% 0.95 [0.06, 16.27] ingelyn 2004 4 30 2 30 4.4% 2.15 [0.36, 12.76] Wang 2019 4 20 5 21 5.2% 0.80 [0.18, 3.54] (ao 2019 9 48 7 47 6.3% 1.32 [0.45, 3.89] Total events 24 30 Heterogeneity: Tau <sup>2</sup> = 0.23; Chi <sup>2</sup> = 7.87, df = 6 (P = 0.25); l <sup>2</sup> = 24% Fest for overall effect: Z = 0.58 (P = 0.56) L4.6 Local tenderness Abdallah 2020 5 67 0 69 2.4% 12.23 [0.66, 225.70] Divesen 2014 3 23 4 22 4.8% 0.68 [0.13, 3.43] Divesen 2014 3 0 1 30 2.6% 0.40 [0.06, 16.76] (ao 2019 4 48 8 47 5.8% 0.44 [0.12, 1.59] Divesen 2014 1 30 1 30 2.6% 0.90 [0.27, 3.02] Total events 13 13 Heterogeneity: Tau <sup>2</sup> = 0.52; Chi <sup>2</sup> = 4.58, df = 3 (P = 0.21); l <sup>2</sup> = 35% Test for overall effect: Z = 0.17 (P = 0.87)	
4.4 S Vomiting         uyong 2018       2       60       9       61       4.9%       0.20       [0.04, 0.96]         im 2020       2       20       0       20       2.2%       5.54       [0.25, 123, 0.8]         iu 2020       2       54       6       53       4.7%       0.30       [0.06, 1.57]         vesen 2014       1       23       1       22       2.5%       0.95       [0.06, 16, 27]         ingelyn 2004       4       30       2       30       4.4%       2.15       [0.36, 12, 76]       -         vang 2019       4       20       5       21       5.2%       0.80       [0.18, 3.54]       -         vang 2019       9       48       7       47       6.3%       1.32       [0.45, 3.89]       -         valotal (95% CI)       255       254       30.4%       0.80       [0.38, 1.68]       -         veterogeneity: Tau <sup>2</sup> = 0.23; Chi <sup>2</sup> = 7.87, df = 6       (P = 0.25); l <sup>2</sup> = 24%       24       80       (0.86       [0.13, 3.43]       -         Adla 202       5       67       0       69       2.4%       10.28       [0.66, 225.70]       -	
Auyong 2018       2       60       9       61       4.9%       0.20       0.02       0.00       0.02       0.2%       5.54       10.20       10.20       10.20       2       20       0       20       2.2%       5.54       10.25       12.2%       5.54       10.25       12.2%       5.54       10.25       12.2%       5.54       10.25       12.2%       5.54       10.25       12.2%       5.54       10.2%       12.2%       5.54       10.2%       12.2%       5.54       10.2%       12.2%       5.54       10.2%       12.2%       12.2%       0.60       16.2.71	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	-
uu 2020       2       54       6       53       4.7%       0.30 [0.06, 15.7]         vesen 2014       1       23       1       22       2.5%       0.95 [0.06, 16.27]         ingelyn 2004       4       30       2       30       4.4%       2.15 [0.36, 12.76]	
Jvesen 2014       1       23       1       22       2.5%       0.95 [0.06, 16.27]         Varge 2019       4       30       2       30       4.4%       2.15 [0.36, 12.76]         Varge 2019       4       20       5       21       5.2%       0.80 [0.18, 3.54]         (ao 2019       9       48       7       47       6.3%       1.32 [0.45, 3.89]         (ao 2019       255       254       30.4%       0.80 [0.38, 1.68]	<b>—</b>
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
rang 2019       4       20       5       21       5.2%       0.80 [0.18, 3.54]         ao 2019       9       48       7       47 $6.3\%$ 1.32 [0.45, 3.89]       -         ubtotal (95% Cl)       255       254       30.4%       0.80 [0.38, 1.68]       -         iotal events       24       30       -       -       -       -         eterogeneity: Tau <sup>2</sup> = 0.23; Chi <sup>2</sup> = 7.87, df = 6 (P = 0.25); l <sup>2</sup> = 24%       -       -       -       -         eterogeneity: Tau <sup>2</sup> = 0.23; Chi <sup>2</sup> = 7.87, df = 6 (P = 0.25); l <sup>2</sup> = 24%       -       -       -       -         .46 Local tenderness       -       -       -       -       -       -       -         .46 Jallah 2020       5       67       0       69       2.4%       12.23 [0.66, 225.70]       -       -         vesen 2014       3       23       4       22       4.8%       0.68 [0.13, 3.43]       -       -         ingelyn 2004       1       30       1       30       2.6%       0.00 [0.66, 16.76]       -         ubtotal (95% Cl)       168       168       15.6%       0.90 [0.27, 3.02]       -       -         otal events       13       13 </td <td></td>	
The form of the second	
L4.6 Local tenderness       30         bdeta verts       24       30         ieterogeneity: Tau <sup>2</sup> = 0.23; Chi <sup>2</sup> = 7.87, df = 6 (P = 0.25); l <sup>2</sup> = 24%       12.23 [0.66, 225.70]         lest for overall effect: Z = 0.58 (P = 0.56)       12.23 [0.66, 225.70]         lest for overall effect: J = 0.23; Chi <sup>2</sup> = 35 (P = 0.56)       12.23 [0.66, 225.70]         vesen 2014       3       23       4       22       4.8%       0.68 [0.13, 3.43]         vesen 2014       3       23       4       22       4.8%       0.68 [0.12, 1.3, 3.43]       130         ingelyn 2004       1       30       1       30       2.6%       1.00 [0.06, 16.76]       168         isubtotal (95% Cl)       168       168       15.6%       0.90 [0.27, 3.02]       148         fotal events       13       13       13       13       13         feterogeneity: Tau <sup>2</sup> = 0.52; Chi <sup>2</sup> = 4.58, df = 3 (P = 0.21); l <sup>2</sup> = 35%       13       13       13         feter for overall effect: Z = 0.17 (P = 0.87)       13       13       13	
oral events       24       24       30         eterogeneity: $Tau^2 = 0.23$ ; $Chi^2 = 7.87$ , $df = 6$ (P = 0.25); $l^2 = 24\%$ 30         'est for overall effect: Z = 0.58 (P = 0.56)	
.4.6 Local tenderness         .bdallah 2020       5       67       0       69       2.4%       12.23       [0.66, 225.70]         bvesen 2014       3       23       4       22       4.8%       0.68       [0.13, 3.43]         ingelyn 2004       1       30       1       30       2.6%       1.00       [0.06, 16.76]         ao 2019       4       48       8       47       5.8%       0.44       [0.12, 1.59]         ubtotal (95% CI)       168       168       15.6%       0.90       [0.27, 3.02]       Image: Comparison of the comparison	
Abdallah 2020       5 $67$ 0 $69$ $2.4\%$ $12.23$ $[0.66, 225, 70]$ Ovesen 2014       3       23       4       22 $4.8\%$ $0.68$ $[0.13, 3.43]$ ingelyn 2004       1       30       1       30       2.6% $1.00$ $[0.06, 16.76]$ (ao 2019       4       48       8       47 $5.8\%$ $0.44$ $[0.12, 1.59]$ (ao 2019       4       48       8       47 $5.8\%$ $0.44$ $[0.12, 1.59]$ (ao 2019       4       48       8       47 $5.8\%$ $0.44$ $[0.12, 1.59]$ (ao 2019       168       168       15.6% $0.90$ $[0.27, 3.02]$ $-763$ Total events       13       13       13       13 $-763$ $-763$ $-763$ Test for overall effect: Z = 0.17 (P = 0.87) $12^{-9}35\%$ $-7535\%$ $-7535\%$ $-7535\%$ $-7535\%$ $-7535\%$ $-7535\%$ $-7555\%$ $-755\%$ $-755\%$ $-755\%$ $-755\%$ $-755\%$ $-755\%$ $-755\%$ $-755\%$ $-755\%$ $-755\%$ $-755\%$ $-7$	
Divesen 2014       3       23       4       22       4.8%       0.68 [0.13, 3.43]         ingelyn 2004       1       30       1       30       2.6%       1.00 [0.06, 16, 76]         (ao 2019)       4       48       8       47       5.8%       0.44 [0.12, 1.59]         ubtotal (95% Cl)       168       168       15.6%       0.90 [0.27, 3.02]         Total events       13       13         teterogeneity: Tau <sup>2</sup> = 0.52; Chi <sup>2</sup> = 4.58, df = 3 (P = 0.21); l <sup>2</sup> = 35%       13         Test for overall effect: Z = 0.17 (P = 0.87)       14	+
ingelyn 2004       1       30       1       30       2.6%       1.00 [0.06, 16.76]         (ao 2019)       4       48       8       47       5.8%       0.44 [0.12, 1.59]         (abtotal (95% Cl)       168       168       15.6%       0.90 [0.27, 3.02]         Total events       13       13         teterogeneity: Tau <sup>2</sup> = 0.52; Chi <sup>2</sup> = 4.58, df = 3 (P = 0.21); l <sup>2</sup> = 35%         Test for overall effect: Z = 0.17 (P = 0.87)	•+
(ao 2019)       4       48       8       47       5.8%       0.44 [0.12, 1.59]         Subtoal (95% CI)       168       168       15.6%       0.90 [0.27, 3.02]         Total events       13       13         Heterogeneity: Tau <sup>2</sup> = 0.52; Chi <sup>2</sup> = 4.58, df = 3 (P = 0.21); l <sup>2</sup> = 35%       13         Test for overall effect: Z = 0.17 (P = 0.87)       13	+
Subtotal (95% CI)       168       168       15.6%       0.90 [0.27, 3.02]         Total events       13       13         Heterogeneity: Tau <sup>2</sup> = 0.52; Chi <sup>2</sup> = 4.58, df = 3 (P = 0.21); I <sup>2</sup> = 35%       13         Fest for overall effect: Z = 0.17 (P = 0.87)	+
Tau1313leterogeneity: Tau $0.52$ ; Chi² $4.58$ , df = 3 (P = $0.21$ ); l² $35\%$ lest for overall effect: Z = $0.17$ (P = $0.87$ )	
Fotal (95% Cl) 1096 1097 100.0% 0.33 [0.19, 0.56]	
Total events 56 169	
Heterogeneity: Tau <sup>2</sup> = 0.89; Chi <sup>2</sup> = 52.11, df = 27 (P = 0.003); l <sup>2</sup> = 48% Test for overall effect: $Z = 4.04$ (P < 0.0001) Suprascapular nerve blo	1 10 200 k Interscalene nerve block
est for subgroup differences: Chi <sup>*</sup> = 18.06, df = 5 (P = 0.003), l <sup>*</sup> = 72.3%	un instalan an CU

syndrome (MD = 0.06, 95% CI [0.02, 0.22], P < 0.0001), numb (MD = 0.05, 95% CI [0.01, 0.33], P = 0.002), subjective dyspnea (MD = 0.4, 95% CI [0.17, 0.95]), hoarseness, (MD = 0.31, 95% CI [0.1, 0.97], P = 0.04). No significant difference was found for vomiting (MD = 0.8, 95% CI [0.38, 1.68], P = 0.56), local tenderness (MD = 0.9, 95% CI [0.27, 3.02], P = 0.87)

The remaining 30% of the joint and capsule is innervated by the axillary, supraclavicular, subscapular, and pectoral nerves [8, 13] rather than the suprascapular nerve.

Management of shoulder surgery pain is often accomplished by using opioids; however, their use is often associated with side effects such as vomiting, nausea dysphoria, respiratory depression, and hormonal effects [32, 37]. The present high-level evidence suggested that the blocks are not different for the critical analgesic measures, namely, the difference between SSNB and ISB in the postoperative oral morphine consumption at 24 h. Likewise, the remaining analgesic outcome results, such as duration of PACU stay, patient satisfaction, and nerve block complications, including vomiting and local tenderness, were consistently not different between the two



groups. In contrast, ISB was associated with a higher incidence of Horner syndrome, numb, subjective dyspnea, and hoarseness. From an anatomical perspective, the SSNB technique needs to perform blocks more distally along the brachial plexus, increasing the distance between block location and the phrenic nerve to decrease the phrenic nerve complications. Many studies also have shown that SSNB is a safe technique [19]. For example, the rate of minor complications was reported by only 0.6% (6/1005) [38]. Moreover, SSNB is an easy technique that can be performed using specific anatomic landmarks alone [33].

Though ISB provides superior pain control during the PACU stay, we did not find any significant difference between SNNB and ISB in terms of duration of PACU stay. Furthermore, no significant difference was found for patient satisfaction in SSNB and ISB, which may be explained by similar pain control in both nerve block techniques.

Our findings may have an impact on clinical practice. The minor analgesic advantages of ISB compared with the SSNB seem to be transient and limited to the immediate postoperative period (PACU stay). In contrast, the risk of block-related complications associated with ISB may outweigh its benefits in certain settings or patient populations, especially when SSNB can offer a safe and effective alternative in patients with severe chronic obstructive pulmonary disease [41], obstructive sleep apnea [10], and morbid obesity [16]. Our findings established the suprascapular block's clinical benefits as an attractive, effective treatment for postoperative pain in patients undergoing shoulder surgery.

#### Limitations

Our meta-analysis has limitations that should be acknowledged. First, heterogeneity was found across the included studies in terms of standardization in anesthetic, nerve block techniques, diversity of shoulder surgeries performed, and the timing of assessment, which precluded the pooling of many of outcomes. Second, some studies included in this review had smaller sample sizes, which may decrease the strength of their effect and limit external validity. Third, the number of the studies comparing the duration of PACU stay (three studies) and patient satisfaction (two studies) is too small. More adequately powered and better-designed RCT studies with these outcomes are needed to reach a firmer conclusion. Fourth, another bias inherent to the present study relates to the inability to blind the operator to the block technique being performed because of the interventions' nature.

### Conclusion

ISB seems to offer minor analgesic advantages that are transient and limited to the immediate postoperative period. SSNB is equal or even better than ISB concerning postoperative pain control in the later time after operation. Furthermore, SSNB does appear to reduce the



risk of Horner syndrome, numb, subjective dyspnea, and hoarseness. Our high-level evidence has established SSNB as an effective, safe, and clinically attractive alternative to ISB during arthroscopic shoulder surgery, especially for patients of severe chronic obstructive pulmonary disease, obstructive sleep apnea, and morbid obesity. Given our meta-analysis's relevant possible biases, we required more adequately powered and better-designed RCT studies with long-term follow-up to reach a firmer conclusion.

#### Abbreviations

Cis: Confidence intervals; RCTs: Randomized controlled trials; RR: Risk ratio; OR: Odds ratio; VMD: Weighted mean difference; BMI: Body mass index; VAS: Visual analog scale; NRS: Numerical rating scale; SSNB: Suprascapular nerve block; ISB: Interscalene block

#### Acknowledgements

Not applicable.

#### Authors' contributions

Changjiao Sun and Xu Cai: Conceptualization, Data curation; Formal analysis, Roles/Writing - original draft; Writing - review and editing. Qi Ma and Xiaolin Ji: Data collection; Investigation; Methodology. Xiaofei Zhang and Peng Yu: Resources; Software. Xu Cai and Huadong Yang (co-corresponding authors): Supervised the whole study. The authors read and approved the final manuscript.

#### Funding

None.

#### Availability of data and materials

The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

#### Declarations

**Ethics approval and consent to participate** Not applicable.

#### Consent for publication

Not applicable.

#### **Competing interests**

The authors declare that they have no competing interests.

#### Author details

<sup>1</sup>Department of Orthopedic, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, No. 168 Litang Road, Dongxiaokou Town, Changping District, Beijing 102218, China. <sup>2</sup>Department of Anesthesia, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, No. 168 Litang Road, Dongxiaokou Town, Changping District, Beijing 102218, China. <sup>3</sup>Department of Clinical Epidemiology and Biostatistics, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, No. 168 Litang Road, Dongxiaokou Town, Changping District, Beijing 102218, China. <sup>4</sup>Department of Orthopedic, Wuhan University of Science and Technology Hospital, Qingling Street, Hongshan District, Wuhan 102218, China.

#### Received: 2 April 2021 Accepted: 2 June 2021 Published online: 11 June 2021

#### References

 Abdallah FW, Wijeysundera DN, Laupacis A, Brull R, Mocon A, Hussain N, et al. Subomohyoid anterior suprascapular block versus interscalene block for arthroscopic shoulder surgery: a multicenter randomized trial. Anesthesiology. 2020;132(4):839–53. https://doi.org/10.1097/aln. 000000000003132.

- Al-Kaisy A, McGuire G, Chan VW, Bruin G, Peng P, Miniaci A, et al. Analgesic effect of interscalene block using low-dose bupivacaine for outpatient arthroscopic shoulder surgery. Reg Anesth Pain Med. 1998;23(5):469–73. https://doi.org/10.1097/00115550-199823050-00007.
- Auyong DB, Hanson NA, Joseph RS, Schmidt BE, Slee AE, Yuan SC. Comparison of anterior suprascapular, supraclavicular, and interscalene nerve block approaches for major outpatient arthroscopic shoulder surgery: a randomized, double-blind, noninferiority trial. Anesthesiology. 2018;129(1): 47–57. https://doi.org/10.1097/aln.00000000002208.
- Bishop JY, Sprague M, Gelber J, Krol M, Rosenblatt MA, Gladstone JN, et al. Interscalene regional anesthesia for arthroscopic shoulder surgery: a safe and effective technique. J Shoulder Elbow Surg. 2006;15(5):567–70. https:// doi.org/10.1016/j.jse.2006.01.009.
- Bogdanov A, Loveland R. Is there a place for interscalene block performed after induction of general anaesthesia? Eur J Anaesthesiol. 2005;22(2):107– 10. https://doi.org/10.1017/s0265021505000207.
- Breu A, Eckl S, Zink W, Kujat R, Angele P. Cytotoxicity of local anesthetics on human mesenchymal stem cells in vitro. Arthroscopy. 2013;29(10):1676–84. https://doi.org/10.1016/j.arthro.2013.06.018.
- Cao S, Wang J, Yan L, Gong W, Zhang Y, Fei W. Analysis of the effect of suprascapular nerve block guided by shoulder arthroscopy in postoperative analgesia of rotator cuff injury. Chin J Endoscopy. 2019;11:55–60.
- Chan CW, Peng PW. Suprascapular nerve block: a narrative review. Reg Anesth Pain Med. 2011;36(4):358–73. https://doi.org/10.1097/AAP.0b013e31 82204ec0.
- Conn RA, Cofield RH, Byer DE, Linstromberg JW. Interscalene block anesthesia for shoulder surgery. Clin Orthop Relat Res. 1987;216:94–8.
- D'Apuzzo MR, Browne JA. Obstructive sleep apnea as a risk factor for postoperative complications after revision joint arthroplasty. J Arthroplasty. 2012;27(8):95–8. https://doi.org/10.1016/j.arth.2012.03.025.
- Desroches A, Klouche S, Schlur C, Bauer T, Waitzenegger T, Hardy P. Suprascapular nerve block versus interscalene block as analgesia after arthroscopic rotator cuff repair: a randomized controlled noninferiority trial. Arthroscopy. 2016;32(11):2203–9. https://doi.org/10.1016/j.arthro.2016.03.013.
- Dhir S, Sondekoppam RV, Sharma R, Ganapathy S, Athwal GS. A comparison of combined suprascapular and axillary nerve blocks to interscalene nerve block for analgesia in arthroscopic shoulder surgery: an equivalence study. Reg Anesth Pain Med. 2016;41(5):564–71. https://doi.org/10.1097/aap. 000000000000436.
- Fernandes MR, Barbosa MA, Sousa AL, Ramos GC. Suprascapular nerve block: important procedure in clinical practice. Rev Bras Anestesiol. 2012; 62(1):96–104. https://doi.org/10.1016/s0034-7094(12)70108-3.
- Flohr-Madsen S, Ytrebø LM, Valen K, Wilsgaard T, Klaastad Ø. A randomised placebo-controlled trial examining the effect on hand supination after the addition of a suprascapular nerve block to infraclavicular brachial plexus blockade. Anaesthesia. 2016;71(8):938–47. https://doi.org/10.1111/anae.13504.
- Fujimura N, Namba H, Tsunoda K, Kawamata T, Taki K, Igarasi M, et al. Effect of hemidiaphragmatic paresis caused by interscalene brachial plexus block on breathing pattern, chest wall mechanics, and arterial blood gases. Anesth Analg. 1995;81(5):962–6. https://doi.org/10.1097/00000539-199511000-00012.
- Griffin JW, Novicoff WM, Browne JA, Brockmeier SF. Morbid obesity in total shoulder arthroplasty: risk, outcomes, and cost analysis. J Shoulder Elbow Surg. 2014;23(10):1444–8. https://doi.org/10.1016/j.jse.2013.12.027.
- Hadzic A, Williams BA, Karaca PE, Hobeika P, Unis G, Dermksian J, et al. For outpatient rotator cuff surgery, nerve block anesthesia provides superior same-day recovery over general anesthesia. Anesthesiology. 2005;102(5): 1001–7. https://doi.org/10.1097/0000542-200505000-00020.
- Harmon D, Hearty C. Ultrasound-guided suprascapular nerve block technique. Pain Physician. 2007;10(6):743–6.
- Hussain N, Goldar G, Ragina N, Banfield L, Laffey JG, Abdallah FW. Suprascapular and interscalene nerve block for shoulder surgery: a systematic review and meta-analysis. Anesthesiology. 2017;127(6):998–1013. https://doi.org/10.1097/aln.00000000001894.
- Ikemoto RY, Murachovsky J, Prata Nascimento LG, Bueno RS, Oliveira Almeida LH, Strose E, et al. Prospective randomized study comparing two anesthetic methods for shoulder surgery. Rev Bras Ortop. 2010;45(4):395–9. https://doi.org/10.1016/s2255-4971(15)30386-4.
- Jiang H, Wu Q, Tang Y, Zheng M, Chen L. Application of ultrasound-guided anterior suprascapular nerve block in the analgesia of shoulder arthroscopic surgery. J Clin Anesthesiol. 2017;12:1192–5.

- Kay J, Memon M, Hu T, Simunovic N, Duong A, Paul J, et al. Suprascapular nerve blockade for postoperative pain control after arthroscopic shoulder surgery: a systematic review and meta-analysis. Orthop J Sports Med. 2018; 6(12):2325967118815859. https://doi.org/10.1177/2325967118815859.
- Konradsen LKP, Larsen VHBH. Suprascapular nerve block or interscalene brachial plexus block for pain relief after arthroscopic acromioplasty. Ambul Surg. 2009;15:16–9.
- Krone SC, Chan VW, Regan J, Peng P, Poate EM, McCartney C, et al. Analgesic effects of low-dose ropivacaine for interscalene brachial plexus block for outpatient shoulder surgery-a dose-finding study. Reg Anesth Pain Med. 2001;26(5):439–43. https://doi.org/10.1053/rapm.2001.25914.
- Kumara AB, Gogia AR, Bajaj JK, Agarwal N. Clinical evaluation of post-operative analgesia comparing suprascapular nerve block and interscalene brachial plexus block in patients undergoing shoulder arthroscopic surgery. J Clin Orthop Trauma. 2016;7(1):34–9. https://doi.org/10.1016/j.jcot.2015.09.003.
- Laurila PA, Löppönen A, Kanga-Saarela T, Flinkkilä T, Salomäki TE. Interscalene brachial plexus block is superior to subacromial bursa block after arthroscopic shoulder surgery. Acta Anaesthesiol Scand. 2002;46(8): 1031–6. https://doi.org/10.1034/j.1399-6576.2002.460818.x.
- Lenters TR, Davies J, Matsen FA 3rd. The types and severity of complications associated with interscalene brachial plexus block anesthesia: local and national evidence. J Shoulder Elbow Surg. 2007;16(4):379–87. https://doi. org/10.1016/j.jse.2006.10.007.
- Li T. Comparison of two ultrasound-guided nerve block techniques in shoulder arthroscopic surgery [Master]. Kunming: Kunming Medical University; 2018.
- Lim YC, Koo ZK, Ho VW, Chang SS, Manohara S, Tong QJ. Randomized, controlled trial comparing respiratory and analgesic effects of interscalene, anterior suprascapular, and posterior suprascapular nerve blocks for arthroscopic shoulder surgery. Korean J Anesthesiol. 2020;73(5):408–16. https://doi.org/10.4097/kja.20141.
- 30. Liu P. The effect of suprascapular nerve block on patients undergoing arthroscopic shoulder surgery. Zhejiang J Traumat Surg. 2020;25:589–90.
- Mai Z. Application of ultrasound-guided anterior suprascapular nerve block in the analgesia of shoulder arthroscopic surgery. J Minimal Invasive Med. 2019;14:803–804+820.
- Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician. 2010; 13(5):401–35.
- Matsumoto D, Suenaga N, Oizumi N, Hisada Y, Minami A. A new nerve block procedure for the suprascapular nerve based on a cadaveric study. J Shoulder Elbow Surg. 2009;18(4):607–11. https://doi.org/10.1016/j.jse.2009.01.005.
- Ovesen JF-JTC. A comparison of subacromial bursae block, suprascapular nerve block and interscalene brachial plexus block after arthroscopic shoulder surgery. Pain Stud Treat. 2014;2(03):107–12. https://doi.org/10.4236/ pst.2014.23017.
- Petroff D, Wiegel M, Pech V, Salz P, Mrongowius J, Reske AW. Differential lung ventilation assessed by electrical impedance tomography in ultrasound-guided anterior suprascapular nerve block vs. interscalene brachial plexus block: a patient and assessor-blind, randomised controlled trial. Eur J Anaesthesiol. 2020;37(12):1105–14. https://doi.org/10.1097/eja. 000000000001367.
- Ritchie ED, Tong D, Chung F, Norris AM, Miniaci A, Vairavanathan SD. Suprascapular nerve block for postoperative pain relief in arthroscopic shoulder surgery: a new modality? Anesth Analg. 1997;84(6):1306–12. https://doi.org/10.1097/00000539-199706000-00024.
- Seyfried O, Hester J. Opioids and endocrine dysfunction. Br J Pain. 2012;6(1): 17–24. https://doi.org/10.1177/2049463712438299.
- Shanahan EM, Shanahan KR, Hill CL, Ahern MJ, Smith MD. Safety and acceptability of suprascapular nerve block in rheumatology patients. Clin Rheumatol. 2012;31(1):145–9. https://doi.org/10.1007/s10067-011-1813-3.
- Shin YDHJ. The effect of sono-guided brachial plexus block on postoperative pain control for arthroscopic shoulder surgery: comparison with general anesthesia. Anesth Pain Med. 2010;5:183–6.
- Singelyn FJ, Lhotel L, Fabre B. Pain relief after arthroscopic shoulder surgery: a comparison of intraarticular analgesia, suprascapular nerve block, and interscalene brachial plexus block. Anesth Analg. 2004;99:589–92. https://doi. org/10.1213/01.Ane.0000125112.83117.49.
- 41. Urmey WF, Talts KH, Sharrock NE. One hundred percent incidence of hemidiaphragmatic paresis associated with interscalene brachial plexus

anesthesia as diagnosed by ultrasonography. Anesth Analg. 1991;72(4):498– 503. https://doi.org/10.1213/00000539-199104000-00014.

- Wang Y. Study on the effect of two continuous nerve blocks on the respiratory function of patients after shoulder arthroscopy [Master]. Kunming: Kunming Medical University; 2019.
- Wiegel M, Moriggl B, Schwarzkopf P, Petroff D, Reske AW. Anterior suprascapular nerve block versus interscalene brachial plexus block for shoulder surgery in the outpatient setting: a randomized controlled patientand assessor-blinded trial. Reg Anesth Pain Med. 2017;42(3):310–8. https:// doi.org/10.1097/aap.00000000000573.
- 44. Yao J, Huang H, Huang S, Zhang Z. Application effect of suprascapular nerve block in patients undergoing arthroscopic rotator cuff repair surgery. Tianjin Med J. 2019;47:851–4.

# **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- · thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

